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ABSTRACT
Monoclonal antibodies and proteins derived from them are an emerging class of anticancer
therapeutics that have shown efficacy in a range of blood and solid tumors. Antibodies
targeting solid tumors face considerable transport barriers in vivo, including blood clearance,
extravasation, diffusion within the tumor interstitium, binding to antigen, endocytosis, and
degradation. The unique pathology of the blood supply to solid tumors only serves to
exacerbate these problems.
A consequence of poor delivery of antibodies to solid tumors is a characteristic perivascular
distribution of antibodies around tumor blood vessels. Often, antibodies bind only cells within
a few cell layers of blood vessels, leaving large areas of tumor cells farther from perfused
vessels completely untargeted. This phenomenon has been observed in multiple studies
involving different antibodies, antigens, and tumor types, both in animal models and in clinical
settings. In this thesis, the perivascular localization of antibodies is explored as a function of
quantitative parameters of the antibody and associated antigen. A novel experimental system
to quantitatively determine bound antibody levels, antigen levels, and blood vessel localization
on a microscopic scale throughout entire tumor cross sections has been developed. This
system has been used to quantitatively measure antibody and antigen distribution in tumor
tissue under a variety of conditions. Effects of varying antibody dose, antibody affinity, and
tumor type and site have been explored and quantitated using this model.
To guide experimental design, we have developed a simplified mathematical model of the
tumor vasculature. This model offers insights into the effects of antigen and antibody
parameters, including dose, affinity, antigen density, and endocytosis rates, which are
measurable in vivo and affect antibody penetration into tumor tissue. A simple scaling analysis
further allows the quantitative determination of the minimum antibody dose required to
saturate a tumor given the antigen turnover rate and density. Together, the mathematical
model and quantitative experimental analysis allow conclusions to be made regarding antibody
design and antigen selection for improved tumor penetration of therapeutic antibodies.
Thesis Supervisor: Dr. K. Dane Wittrup
Title: C.P. Dubbs Professor of Chemical Engineering and Biological Engineering
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1. INTRODUCTION
1.1 Background
Cancer encompasses a diverse set of diseases which are characterized by the unconstrained
growth of cells within the host's body '. Worldwide, cancer is a leading cause of mortality,
killing in excess of 7.6 million people each year 2. In the United States, cancer is diagnosed in
over 1.6 million patients each year, killing nearly 600,000 annually or approximately one in four
deaths 4. Despite decades of research and significant progress understanding the origins and
pathology of cancer, it remains a difficult disease to treat, in large part because the cancer cells
arise from the tissue of the host.
Traditional treatments for cancer make up the bulk of modern clinical treatments, and can be
divided into three categories: surgery, radiation, and chemotherapy. Surgery involves the
invasive excision of the tumor, and when successful is often curative. However, it requires that
the location of the tumor be known and accessible to surgical intervention. Surgery is also
ineffective against metastatic disease or tumors too small to be detected by current medical
imaging techniques s. Likewise, radiation is often able to shrink or even ablate tumors, but
requires that the location of the tumor be accurately known. Radiation also causes damage to
healthy tissue in and nearby the path of the radiation. In contrast, chemotherapeutics are
cytotoxic drugs which are typically administered systemically and target rapidly dividing cells, of
which tumor cells are only a subtype. As a result, chemotherapy may be effective against
tumors of varying sizes and locations in the body, including micrometastases and other tumors
too small to be detected. However, the drugs exert a nonspecific effect and affect all rapidly
dividing cells of the body, causing substantial side effects and damage to healthy tissue.
New cancer treatments that retain the benefit of systemic administration while improving
tumor-specific targeting are under development and some have recently advanced to clinical
use. These treatments are generally targeted to molecules which are selectively expressed,
upregulated, or mutated specifically in cancer cells. This thesis is focused on a particular class
of molecules, antibodies, which target and bind cancer cell antigens. Antibodies can exert
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antitumor effects in a number of ways by binding antigen, including by altering receptor
function (e.g. ligand blocking or receptor downregulation), activating the host immune system,
or by selectively delivering a cytotoxic drug directly and selectively to the tumors cells 6. They
have been successfully developed as drugs in the context of many different cancer types, from
blood cancers to solid tumors of several different organs, and represent an important and
growing field of research and drug development.
1.2 Antibody treatment of cancer
Antibodies are an important part of the adaptive immune system. They are able to recognize
an enormous array of foreign pathogens with a high degree of specificity. The most prevalent
subtype of antibody, immunoglobulin G (IgG), is the focus of most research into therapeutic
antibodies and will be the focus of this thesis. It is a 150 kDa protein that consists of two
identical binding domains joined to a constant domain that has functions including recruitment
of immune responses and extension of antibody serum half life 7.
Antibodies can be engineered to attain or enhance certain properties, such as specificity to a
certain target antigen, binding affinity to that antigen, and to some extent recruitment of
immune effector functions and serum stability and persistence 8,10-12. These properties have
made them popular scaffolds for drug discovery and development, and there are currently
twelve antibodies or antibody-drug conjugates which are approved for clinical use in the United
States or Europe.6. There are dozens of antibodies which are in various stages of clinical trials
for oncology indications, and hundreds more for other diseases.
Another appeal of antibodies as therapeutics is the diverse mechanisms by which they can
exert anti-tumor effects. Antibodies can engage the immune system through activation of
complement, through antibody directed cellular cytotoxicity (ADCC), by blocking access of
ligand to cell surface receptors, or by otherwise modulating cellular signaling 6,14. By virtue of
their highly specific targeting, antibodies have also found use as carriers for cytotoxic agents to
deliver them specifically to tumors. These agents include toxins, which are conjugated to the
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antibody and delivered intracellularly to targeted cells, as well as radionuclides which emit
damaging radiation to cells in the vicinity of targeted tissue 15-18. Finally, a significant focus of
research and preclinical drug development lies in using nanoparticles as anticancer agents, and
these are often targeted to tumors by conjugating antibodies or antibody fragments to the
nanoparticles9 ,20
Unlike traditional methods of cancer treatment, antibodies can be administered systemically
and be highly targeted to tumor cells. Because of this unique combination of traits, they were
called "magic bullets" by Paul Ehrlich nearly a century ago21 . However, realization of the
potential of antibodies as therapeutics has been slow, and recently some of the barriers to the
realization of the potential of antibodies as cancer therapeutics have become apparent.
At approximately 150 kDa in size, antibodies are orders of magnitude larger than most
chemotherapeutics (Figure 1.1). Because of their size and complexity, antibodies can be
"engineered" for desirable properties such as stability, binding affinity and specificity, and
immune effector functions8 ,10,12. However, their large size also has deleterious effects on
antibody diffusivity and vascular permeability, potentially limiting their access to extravascular
targets2-26 . There is some empirical evidence of this in the form of the FDA-approved antibody
therapeutics in the clinic. In 2009, 5 of the 9 approved anticancer antibodies were against
blood cancers, despite these making up just 10-15% of all cancer diagnoses. This observation is
significant because blood cancers are much easier targets for intravenously delivered
therapeutics such as antibodies than are solid tumors. Active areas of research in antibody
engineering as well as antigen selection and antibody pharmacokinetics are seeking methods to
improve the delivery of antibodies to solid tumors.
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Figure 1.1. Comparison of size of a representative small molecule chemotherapeutic (doxorubicin, at
left) with monoclonal antibodies (murine lgG2a, at right) 7. For comparision, the molecular mass of
doxorubicin is about 544 Da, whereas antibodies measure approximately 150,000 Da. This difference in
size and complexity creates dramatically different properties between the two classes of molecules.
These differences in turn dictate behavior of these molecules in vivo, including their administration,
plasma clearance behavior and rate, vascular permeability, diffusivity, binding properties, and routes
and rates of metabolism.
1.3 In vivo tumor targeting
All antibody therapeutics which are currently in clinical use are administered intravenously,
giving them access to the systemic circulation and also exposing them to numerous routes of
clearance and barriers to efficient delivery to the tumor tissue. Often, the result of
administration of antibody therapeutics is that only a small fraction, generally only a fraction of
a percent of the injected dose per gram of tumor tissue, reaches the tumor tissue 28-30. There
are many factors which contribute to the poor delivery of antibodies to tumor tissue, including
properties of the antibody itself as well as the pathological nature of blood flow in the tumor
space.
The delivery of macromolecules to solid tumors can be separated into two distinct parts based
upon length scales. First and best described in the literature is the bulk accumulation of the
drug administered. From this perspective, the greatest accumulation of the therapeutic in the
organ of interest, in this case the tumor, and the lowest accumulation in other organs is
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typically desired. Bulk accumulation can be measured preclinically with a high degree of
accuracy using necropsy to obtain a quantitative biodistribution at a certain time point31'32. It
can also be measured preclinically as well as in the clinic using noninvasive imaging
technologies such as microCT, magnetic resonance imaging (MRI), positron emission
tomography (PET), and in some cases fluorescence ,33-38 . These methods can be useful for
exploring the time course of tissue accumulation.
Bulk accumulation is also amenable to pharmacokinetic modeling. Using in vitro measurements
of molecular properties, such as stability, size, and binding affinity, and in vivo measurements of
parameters such as plasma clearance rate and biodistribution, the distribution and in some
cases efficacy of therapeutics can be mathematically modeled to give predictions that can be
applied to preclinical studies and even scaled to clinical studies28 ,39-41. Many of these models
are compartmental in nature, and treat organs or organ systems as compartments between
which drugs can be exchanged at rates which are typically fit to experimental data. As a
consequence, both pharmacokinetic models and experimental analyses such as in vivo imaging
and necropsy are limited in that they hold that organs, including the tumor, can be assumed to
be well mixed compartments. While they may be useful for measuring and predicting the
accumulation of antibodies in tissues, they fail to consider how the antibodies distribute within
the tissue and simply assume that antibodies distribute in a homogeneous fashion.
However, the assumption that antibodies distribute homogeneously within tumor tissue has
been shown to be false. When tumors are examined at a microscopic scale, it becomes clear
that antibodies and other binding macromolecules such as targeted nanoparticles distribute in
a perivascular fashion 22,42-47. Tumor cells which are within a few cell layers of perfused vessels
are often well targeted, but viable tumor cells which are located slightly farther away from
these vessels are often poorly targeted or completely untargeted (Figure 1.2). This
phenomenon has been observed preclinically in a range of cases, including different tumor cell
lines, antigens, and antibodies. Perivascular localization of antibody therapeutics has also been
observed in the case of some antibodies which are currently FDA approved, including
Herceptin, Cetuximab, and Panitumumab 43,48,49. There is also evidence that poor tumor
penetration is observed in the clinic, although the evidence is less compelling 50. For
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therapeutics which must reach cells to be effective, such as those which block ligand binding or
must be internalized to be effective, these untargeted regions represent a real problem. For
other therapeutic modalities which can act from a distance, such as radioimmunotherapeutics
or immunotherapies which recruit immune cells to the site of disease, the problem of poor
tissue penetration may not be so significant.
'4V
Figure 1.2. Examples of poor penetration of antibodies into solid tumors. At left, trastuzumab
(Herceptin), clinically approved monoclonal antibody, penetrates poorly into a xenograft cancer
model4 8. Light blue denotes blood vessels, dark blue represents a perfusion marker, and dark brown
represents trastuzumab. At right, an anti-CEA antibody exhibits heterogeneous distribution in a
xenograft model of cancer. Green represents blood vessels, blue anti-CEA antibody, and red areas of
hypoxia24
Antibody delivery to and distribution within solid tumors is hindered by a number of factors.
Although antibodies typically have extremely long half lives relative to other similarly-sized
molecules due to neonatal Fc receptor (FcRn) recycling, they are nonetheless large molecules
which are larger than the pores typically found in blood vessels51,5 2. Tumors, however, possess
a pathological network of blood vessels. The process of neoangiogenesis does not occur under
normal conditions in adults, but dysregulation in cancer leads to the secretion of growth factors
including vascular endothelial growth factor (VEGF), a potent stimulant of neoangiogenesis5 3.
Tumors which grow over a size of approximately one millimeter must recruit a new blood
supply to grow further, and begin overexpression of VEGF to recruit a vasculature5 4. The newly
formed blood vessels do not form in an orderly manner-instead, they form convoluted,
unpredictable networks with many shunts, dead ends, and oops25,5-57. They are also much
12
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more leaky than normal blood vessels, a phenomenon which has substantial implications for
drug delivery to solid tumors5 3,58 . The result of the irregular nature of the blood vessels that
form in the tumor is that many blood vessels that form do not perform their functions
efficiently, and in many cases are nonfunctional. This creates irregular perfusion in the tumor
and areas with poor or no delivery of blood 58- 0.
As a consequence of their enhanced leakiness and larger pore sizes than normal blood vessels,
tumor vessels allow fluids and macromolecules to extravasate much more readily than healthy
vessels6i,62. Most solid tumors do not drain extravasated fluid well because they generally lack
a functional lymphatic system6 3,64 . As a result, the interstitial fluid pressure (IFP) in the tumor is
typically quite high, and often nearly matches the pressure in the tumor blood vessels61' 65 . This
lack of a substantial pressure gradient diminishes the convective flow of blood and
macromolecules in the blood to a level that it can generally be neglected relative to diffusive
transport22,6s- . For large molecules, such as antibodies and nanoparticles, which diffuse
slowly because of their large sizes, the lack of convective transport substantially impedes the
transport of these molecules into the tumor space.
Antibodies which do extravasate and diffuse into the tumor space then face another barrier to
efficient, homogeneous distribution in the form of binding to antigen*6 47 '69. Once bound to cell
surface antigen, antibodies are subject to the trafficking of the antigen. Often, antigens and
bound antibodies are endocytosed and degraded, or sometimes recycled to the cell surface.
Most antibodies for therapeutic applications are chosen or engineered to have a high affinity,
often with dissociation half times on the order of hours or more. Since constitutive membrane
turnover occurs with a half time of approximately 12 hours, this means that antibodies often
bind only one antigen, and that they are endocytosed and degraded at the site of that
70antigen
The effects of antigen-mediated antibody catabolism have been well documented
experimentally. Using well controlled in vitro experiments, the rates of diffusion, binding,
endocytosis, and degradation can be compared to determine how each affects tissue
penetration ' . Applying a scaling analysis analogous to the Thiele modulus used in chemical
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engineering analyses of chemical kinetics, it is possible to make a quantitative prediction of the
distance penetrated into a three dimensional tumor spheroid as a function of antibody and
antigen properties. This scaling analysis was shown to be highly predictive of penetration time
and distance in this experimental system73. It was extended in other work to allow penetration
into spheroids to be predicted by easily measured antibody and antigen parameters:
R D [Ab]
k, ([Ag] /s)
Where R is the radius penetrated, D is antibody diffusivity, [Ab]surface is the antibody
concentration at the spheroid surface (bulk concentration), ke is the endocytosis rate, [Ag]tumor
is the antigen concentration in the spheroid, and E is the void fraction in the spheroid. This
simple expression was tested varying [Absurface, changing [Ag]tumor through the use of different
cell lines, and by altering ke through changing incubation temperature. In all cases, the
quantitative predictions of the scaling analysis were able to capture the fundamental behavior
of the process, and were generally quantitatively precise within approximately a factor of
tW72,73.two""
These models illustrate the power of mathematical models, even simple scaling analyses, to
capture salient features and make quantitative predictions in complex biological systems. The
next step in the development of these models is to extend them to the in vivo environment,
which tends to be more complex, more heterogeneous, and more difficult to study
experimentally, particularly in a quantitative fashion. In a tumor, the antibody is delivered by
the vasculature, and must extravasate into the tissue from the vascular compartment. It is
reasonable to ask whether this extravasation step represents a major barrier to antibody
delivery or whether it may be negligible relative to the other barriers, such as plasma clearance
and antibody binding and catabolism.
To address this question, previous research has compared the rate of antibody extravasation to
the rate of diffusion through the tumor interstitium23. Mathematically, this rate is analogous to
the Biot number in engineering and can expressed as:
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Biot = Extravasation rate - 2 PRcap
Diffusion rate D
Using typical values for a molecule of the size of antibody, permeability (P = 3x10-3 pm/s),
capillary radius (Rcap= 10 pm), and diffusivity (D = 14 pm2/s), once finds that Biot is
approximately 0.004 for an antibody23 . The Biot number is therefore much less than one, which
implies that the diffusion rate is much faster than the extravasation rate. Therefore,
extravasation of antibody is a rate limiting process and must be considered in any relevant
experimental or modeling system.
A similar analysis was conducted to further examine the potential limiting rates of antibody
delivery to solid tumors . Two dimensionless parameters were analyzed to determine the
limiting rates under conditions typical of antibodies in vivo. These parameters were ratios of
rates of antibody transport. The first such ratio was termed the clearance modulus and
represented mathematically as:
= Plasma clearance rate R2 ([Ag]/e)
Tumor penetration rate D (A UC.,)
In the above expression, AUCsurf refers to the antibody concentration area under the curve
(AUC) at the surface of the blood vessel. For the clearance modulus, a value less than one
implies that the tumor is penetrated much more rapidly than the drug is cleared from the
plasma. Conversely, a value greater than one implies that the drug is cleared from the plasma
before it is able to fully penetrate the tumor. In the case of antibodies, the clearance modulus
is generally much less than one. This is the case largely because antibodies have very long
serum half-lives, on the order of weeks in humans, due to neonatal Fc rescue and recycling7.
For other therapeutic proteins which have shorter half-lives, the clearance modulus often
indicates that plasma clearance may limit tumor penetration. However, for antibodies, plasma
clearance is generally not a limiting factor.
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The second dimensionless parameter developed to examine tumor transport was termed the
Thiele modulus after the analogous engineering parameter utilized in the study of chemical
catalysis. The Thiele modulus compares the rate of extravasation and diffusion into the tumor
to the rate of antigen-mediated catabolism within the tumor. It can be expressed
mathematically as:
2 _ Extravasation and diffusion time keRKrogh
2
Catabolism time D'2PR [Ablpiasma b] + Kd
D
The terms in this expression will be discussed in detail in section 1.4. Values of the Thiele
modulus less than one imply that the rate of extravasation and diffusion is faster than the rate
of catabolism, and the tumor will be saturated. Values greater than one indicate that
catabolism outweighs extravasation and diffusion, and that the catabolic sink will prevent
antibody from fully penetrating the tumor. The Thiele modulus is often on the order of unity,
and so can give valuable information about whether a tumor will be penetrated. In addition,
this simple mathematical expression can be used to give quantitative information about which
parameters may be limiting tumor penetration.
1.4 Tunable targeting parameters
The dimensional analysis of the Thiele modulus is a valuable quantitative predictor of tumor
penetration. Similar analyses have proven useful and quantitatively accurate in in vitro studies,
and the Thiele modulus represents an extension to considerations of in vivo tumor penetration,
namely the inclusion of the extravasation and diffusion steps. Importantly, the parameters that
make up the Thiele modulus are parameters which can be experimentally measured, and in
many cases are well published in the literature. A discussion of the various parameters and
how they might be altered with the goal of enhancing in vivo tumor penetration follows below.
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Endocytosis rate (ke)-Rate at which tumor antigen is endocytosed. When antibody-bound
antigen is endocytosed, antigen-mediate clearance and degradation of the antibody can be
substantial40' 46',- 75. Antigen endocytosis rates can vary over several orders of magnitude, from
antigen half lives on the order of minutes to constitutive membrane turnover on the order of
12-15 hours. Targeting antigens with slower endocytosis rates can improve tissue penetration
by limiting antigen-mediated antibody catabolism. Some antibody therapeutics, such as
immunotoxins, must be internalized to effectively deliver their cytotoxic payload. For these
therapeutics, faster endocytosis rates may be advantageous, and this must be balanced against
the transport limitations caused by high levels of antigen-mediated internalization and
degradation.
Krogh cylinder radius (RKrogh) - The Krogh cylinder radius is the radius of the idealized cylinder of
tissue surrounding a blood vessel. It was proposed as a model for oxygen and nutrient delivery
to muscle tissue, where capillary beds are orderly and vessels are typically parallel and evenly
spaced76 . The Krogh cylinder radius determines the volume of tissue which surrounds a vessel
and must be supplied with oxygen and nutrients, or in the case of tumor tissue targeted by
therapeutic antibodies. Larger radii imply less dense vascularization, and increase the distance
that antibodies must penetrate the tissue to achieve saturation.
Antigen density ([Ag]) -Antigen density, or antigen concentration, is a function of the cell
density and the number of antigens per cell. In most tumors, cell density is similar, and so the
number of antigens per cell is the main factor determining the antigen density. Most
therapeutic antibodies target antigens which are upregulated in cancer and so often highly
expressed. However, it should be noted that antigen expression can vary significantly, often
over orders of magnitude, even within the same tumor type. There is even evidence that
tumors can alter their antigen expression in response to therapy 77 . In general, high antigen
expression creates more "targets" for antibodies to bind, and so can impede tissue penetration.
The number or fraction of antigens which are desired to be bound is also different for different
mechanisms of action. For example, ligand-blocking antibodies must occupy as many antigens
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as possible, while immunotoxins may be cytotoxic at levels that bind only a small fraction of the
antigen available.
Voidfraction (e) -The void fraction is the fraction of the tumor that is accessible to the
antibody. It is a function of the size of the molecule 8 . Smaller molecules have a higher void
fraction, as they can fit into smaller pores and fluid spaces. Macromolecules such as antibodies,
antibody fragments, and nanoparticles have a much lower void fraction, which serves to
increase the apparent antigen concentration.
Diffusivity (D) - Molecular diffusivity of the molecule. The diffusivity determines how quickly a
molecule moves through a fluid space, such as the tumor interstitium. It is a function of
molecular radius, with diffusivity decreasing with increasing molecular radius. It has been
shown that for molecules around the size of antibodies and in the affinity range of most
therapeutic antibodies, the rate of diffusion is small compared to the rate of binding, and
antibodies typically bind free antigen within the first layer of cells that they encounter.
Permeability (P) -Vascular permeability of the tumor capillary. The permeability of tumor blood
vessels is typically much greater than that of normal blood vessels 26,5 3,79. Permeability is also a
function of molecular size, and larger molecules can have dramatically lower permeability than
smaller molecules78. Vascular permeability can be measured in vivo using techniques such as
dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). The permeability of tumor
blood vessels is a parameter which can be altered by pharmacological means. Some
researchers have argued that some therapeutics such as Avastin, an anti-VEGF antibody, are
efficacious in part because they decrease tumor vascular permeability to a range more
characteristic of healthy vessels and "normalize" tumor vessels64,o-8 2. These vessels would
have permeabilities near the range of healthy vessels, leading to a restoration of a pressure
different between the vessel lumen and the interstitium and inducing convective flow of blood
64components into the tumor . Other researchers have argued that tumor vessels should be
made more permeable, through the use of pharmacological agents such as vascular disrupting
agents or by use of localized hyperthermia 83-86. The increased permeability is thought to
facilitate the diffusion of macromolecules through the blood vessels, resulting in greater tumor
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delivery. Recent research has supported both arguments, and there is mounting evidence to
suggest that changes to vascular permeability can be transient and that therapeutic "windows"
of altered vascular permeability may be present but do not exist for long time periods32,5 3,87,88.
Capillary radius (Rcap) -Radius of the capillary at the center of the Krogh cylinder. The capillary
radius determines the surface area of the vessel, which in turn determines the rate at which
antibody can extravasate. Larger vessels present larger surface areas, and so enable a greater
extravasation rate. Animal models and clinical data have shown that tumor vessels are highly
irregular, often poorly formed, and suffer from poor perfusion and variations of blood flow
rates both spatially and temporally. These pathologies of the vasculature contribute to the
heterogeneous nature of the tumor microenvironment.
Antibody dose ([Ab]pasma) -The dose of the antibody administered. Antibodies are administered
intravenously, giving them immediate access to the systemic circulation. Antibody doses are
typically limited by the nonspecific toxicity of the antibodies. Some antibody-based
therapeutics, such as immunotoxins, are particular toxic and often must be dosed at only a
fraction of the dose at which the naked antibody can be safely administered17' 89. Higher
antibody doses increase tissue penetration in multicellular spheroid models as well as in
xenograft tumor models. Evidence is sparse and somewhat mixed regarding how well tumor
tissue is penetrated at doses typically administered in clinical settings28,90
Antibody affinity (Kd) -The binding affinity of the antibody to its target antigen. The antibody
affinity is a property than can be engineered. Therapeutic antibodies are typically high affinity,
which for the purposes of tumor targeting often means that the characteristic time for
unbinding is quite long relative to the other relevant rates, such as diffusion, binding, and
degradation, and so in many cases the antibody can be considered irreversibly bound. At lower
affinities, antibodies will unbind more rapidly. At very low affinities, antibodies will bind only
very briefly before unbinding. In this extreme, the tissue penetration is expected to be
excellent, but the fraction of antibody bound will be very low. The antibody affinity is a
parameter that can be tuned to provide the desired balance between homogeneous tissue
distribution and degree of antigen binding.
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1.5 Thesis overview
In this thesis, we aim to study the distribution of antibodies in solid tumors. We seek to explore
the properties of the antibody and the antigen that determine how antibodies distribute in the
tumor, and to predict behavior using mathematical modeling. In Chapter 2, we develop an
experimental toolbox that allows the quantitative determination of antibody and antigen
distribution in solid tumor xenograft sections. We then apply this toolbox and mathematical
modeling to determine the effect of antibody dose and antigen endocytosis rate on the
distribution of the antibody within the tumor. In Chapter 3, we explore the effects of antibody
affinity on the distribution of the antibody and the accumulation of the antibody in the tumor.
Chapter 4 is a study of several different antibody dosing schedules to determine their effects on
tumor control and attempt to correlate efficacy to antibody distribution and penetration into
tumor tissue. Chapter 5 examines the effect of xenograft tumor location in a mouse model,
comparing two cell lines in orthotopic and ectopic locations to determine whether tumor
location influences properties of antibody delivery and distribution. Lastly, Chapter 6 details
the development of a novel autochthonous mouse model of cancer. This model is engineered
to knock out the p53 tumor suppressor and constitutively activate the K-Ras oncogene, leading
to development of a cancer which mimics human cancer in its genesis and pathology. This
model is altered by the addition of a virally delivery antigen which allows the study of antibody
therapy in an authochthonous, immunocompetent mouse model of cancer.
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2. ANTIBODY DOSE VS. TUMOR PENETRATION
2.1 Introduction
Antibodies represent a significant and rapidly growing proportion of oncology therapeutics'.
While many have found success in a range of cancers, particularly hematologic malignancies,
there remain substantial barriers to the effective use of antibodies to treat solid tumors. Solid
tumors present a number of barriers to tumor targeting and penetration, including blood
clearance, extravasation, diffusion through the interstitial space, binding to antigen,
end ocytosis, and degradation2 3 . Many of these barriers are further exacerbated by the
disordered physiology of solid tumors which results in highly permeable and irregular
vasculature and high interstitial fluid pressure4- . For decades, researchers have noted that
penetration into solid tumor tissue is often limited for drugs ranging in size and mechanism of
action from chemotherapeutics to antibodies and nanoparticles3,4,7-". Limited penetration has
been linked to reduced therapeutic efficacy, even in cases in which bulk tumor uptake is high
enough to exert an anti-tumor effect with a well distributed therapeutic12" 3 . Recently, it was
shown that the FDA-approved monoclonal antibodies cetuximab, trastuzumab, and
panitumumab penetrate poorly into tumors in animal xenograft models 3-15.
Quantitative in vitro studies of antibody delivery to and distribution within tumor spheroids
have yielded insights into the roles that antibody affinity and antigen internalization play in this
16,17process ' . In vivo, for a range of antibodies, antigens, and cell lines, extravasation from
tumor blood vessels has been shown to display a characteristic perivascular distribution in
which tumor cells within a few cell layers of perfused vessels are often saturated with antibody,
but more distal regions show little to no evidence of therapeutic targeting7,,12,14,is. Common
bulk measures of tumor uptake such as percent injected dose per gram fail to differentiate the
heterogeneity of tumor targeting at the microscopic scale.
Here, we present an in vivo study of monoclonal antibody and antigen distribution around
tumor blood vessels as a function of antibody dose covering two orders of magnitude. A
computer-aided method of analyzing entire tumor cross sections in a quantitative and unbiased
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manner is utilized to generate data. These results are consistent with a Krogh cylinder model
and scaling analysis which predict the antibody dose necessary to saturate a tumor for a given
antigen cell surface expression level and metabolic half-life. Although these modeling analyses
are dramatic oversimplifications of the tumor microenvironment, they are nonetheless
successful in quantitatively predicting the distribution of extravasated antibody averaged over
the tumor cross section.
2.2 Materials and methods
Reagents
A low-picomolar humanized antibody to carcinoembryonic antigen (CEA), designated sm3e, has
previously been engineered and characterized' 8 . This antibody was secreted in transiently
transfected HEK 293 cells (Invitrogen, Carlsbad, CA), purified by protein A resin (Millipore,
Billerica, MA) and buffer exchanged into PBS. The antibody was fluorescently labeled using the
Alexa Fluor 488 Protein Labeling kit from Invitrogen (Carlsbad, CA). Labeling was conducted in a
single batch of approximately 3 mg protein to yield a homogenously labeled reagent source for
all experiments presented. Anti-CEA monoclonal antibody M85151a was purchased from
Fitzgerald (Acton, MA) and goat anti-rat 546 secondary antibody from Invitrogen. Antibody
M85151a was labeled with an Alexa Fluor 647 Protein Labeling kit and has been previously
determined to be noncompetitive with sm3e' 9.
Animal model
Animal use and care was conducted in full compliance and under approval from the MIT
Committee on Animal Care. A CEA-positive human colorectal cancer cell line, LS174T, was used
to induce xenograft formation in the flanks of 6-8 week old Ncr nude mice (Taconic, Hudson,
NY) by subcutaneous injection of 5 x 106 cancer cells. Tumors were allowed to establish and
grow to a diameter of 5-10 mm, at which point antibody injections were conducted. Varying
doses of fluorescently labeled sm3e, ranging from 5 .tg to 500 pg, were supplemented as
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needed with IgG from human serum (Sigma-Aldrich, St. Louis, MO) to 500 pg total IgG, then
injected retroorbitally into tumor bearing nude mice. Mice were sacrificed 24 hours after
antibody administration, and tumors were immediately excised and snap frozen in Optimal
Cutting Temperature (OCT) medium (Sakura Finetek USA, Torrance, CA) via isopentane over
liquid nitrogen. Frozen blocks were stored at -800C until sectioned by the Koch Institute
Histology Core Facility. Frozen blocks were sectioned approximately 1-2 mm into the tumor
tissue at a thickness of 8 pm and stored at -80*C until stained and imaged.
Immunofluorescence protocol
Frozen slides were first air dried for approximately 30 minutes, then tissue samples circled with
a PAP pen (Invitrogen, Carlsbad, CA). Tissues were fixed for 15 minutes at room temperature in
formalin, then washed 3 times with PBS. Blocking was performed with 5% goat serum
(Invitrogen) in PBS for 1 hour at room temp. Primary antibody incubation was 5% goat serum in
PBS + 1:100 rat anti-mouse CD31 (BD Pharmingen, San Diego, CA) overnight at 40C. Slides were
then washed three times with PBS, then incubated with PBS+0.1% Tween 20 (Sigma-Aldrich, St.
Louis, MO) + 1:200 goat anti-rat 546 (Invitrogen, Carlsbad, CA) + 1:100 M85151a-647 anti-CEA
antibody (Fitzgerald, Acton, MA) for 1 hour at room temperature. Slides were washed 4 times
with PBS, then mounted in Vectashield + DAPI medium (Vector Labs, Burlingame, CA).
Fluorescence imaging
Slides were imaged using a DeltaVision Spectris microscope (Applied Precision, Issaquah, WA)
equipped with a motorized stage and running Softworx software (Applied Precision). Emission
and excitation filters were arranged to permit simultaneous 4-color imaging of DAPI, 488, 546,
and 647. The paneling feature of Softworx was used to capture the entire tumor section at a
resolution of 1.336 pm/pixel and to stitch together the fields into a single large mosaic image
for subsequent analysis (Figure 2.1).
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Figure 2.1. Example of resolution and scale of immunofluorescence images. Panel A, full tumor section
with antibody pseudocolored green and CD31 (blood vessels) red. Boxed area denotes approximate
zoomed region in B,C, and D. Scale bar, 1 mm. Panel B, zoomed area from panel A. Scale bar, 50 pm.
Panel C, antigen (CEA) channel in the same region. Panel D, DAPI channel in same region.
2.3 Mathematical modeling
Modeling
Antibody extravasation was modeled using an extension of a previously described Krogh
cylinder model of the tumor vasculature as detailed in Appendix A. Criteria for tumor
saturation were estimated using the Thiele modulus concept described previously and using
parameters extracted from the literature or measured directly in tumor sections. The key
assumption underlying the Thiele modulus is that the extent of antibody distribution through
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the tumor volume is determined by the balance between endocytic consumption of bound
antibody and extravasation/diffusion. The Thiele modulus represents the dimensionless ratio
of these competing rates, and is described mathematically as:
2PR[Ag]
keRkrogh 2  I
D cap [Ablpasma + Kd
D
When <p2 = 1, these characteristic rates are equal and hence saturation of the tumor tissue is
approximately achieved. ke is the endocytic rate constant for antibody/antigen complexes. R
is the average distance to the nearest blood vessel in the tumor. [Ag] is the antigen
concentration on a per-tumor-volume basis. E is the fraction of tumor volume accessible to the
antibody. D is the diffusivity of the antibody in tumor tissue. P is the vascular permeability
coefficient. Rcap is the average capillary radius. [Ab]plasma is the peak plasma concentration
of antibody. KD is the antibody/antigen equilibrium dissociation constant. Parameter values
are given in Table 1.
In addition to the dimensional analysis used in the Thiele modulus, a numerical simulation
based upon the Krogh cylinder geometry was also carried out. This model tracks the
concentrations of the antibody, antigen, bound antibody, and internalized antibody species as a
function of distance from the blood vessel and time. This model assumes that antibody
transport in tumor tissue is dominated by diffusion, as has been shown in the literature202
The numerical simulation is carried out using the Matlab software package. Details of the
simulation are given in Appendix A.
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Krogh cylinder model parameter values
Parameter Definition Value Citation
E Tumor void volume 0.2391 22
D Diffusivity 2.54 x 10-' 22
cm2/s
P Vascular permeability 3.87 x 107 22
cm/s
RKrogh Krogh cylinder radius 60 pm Measured
Rcap Capillary radius 8 pm 23
Kd Monovalent affinity 10 pM Measured
[Ag] Antigen concentration 150 nM 24,25
ke Antigen endocytosis rate 1.3e-5 s-1 19
Table 2.1. Parameter values used in the Thiele modulus analysis of the criteria for tumor saturation in
the case of IgG antibodies and using CEA as a model antigen in LS174T tumor xenografts. Values were
measured by experiment or taken from the literature.
2.4 Results
Unbiased Image Analysis
Rather than introduce potential observer bias by manually selecting individual blood vessels for
analysis, images were analyzed as entire tumor sections for features including intervessel
distance, antibody penetration from blood vessels, and antigen distribution. The 546 nm (blood
vessel) plane was isolated, thresholded to include vessels only, and converted to a binary image
using ImageJ (NIH, Bethesda, MD). A Euclidean distance map was created from the vessel
binary, and this map was used as a mask to measure average intensity in the antibody (488) and
antigen (647) planes as a function of distance from nearest blood vessel by an automated
MATLAB (The Mathworks, Natick, MA) computer script (Figure 2.2). Regions of the tumor
revealed to be necrotic or stromal tissue by examination of H&E staining or by absence of
antigen were excluded from the analysis.
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Figure 2.2. A depiction of an example immunofluorescence image. Objects pseudocolored red indicate
blood vessels, and green pseudocoloring represents extravasasated antibody. Antibody was administed
to the tumor-bearing mouse 24 h before euthanasia at a dose of 50 pg. Not shown for clarity are DAPI
and antigen, both of which are also imaged with blood vessels and antibody. Scale bar, 1 mm. B, blood
vessels have been thresholded and a Euclidean distance map applied to the thresholded vessels.
Antigen negative and necrotic regions of the tumor section can be manually removed from the analysis
of this image. Pixel intensities are directly proportional to distance from nearest blood vessel. C, Output
of the automated MATLAB analysis of antibody distribution from blood vessels. Antibody intensity
values at large distances from blood vessels are indistinguishable from those measured in tumors that
did not receive antibody. Not shown for clarity is the corresponding antigen distribution.
Microdistribution experimental results
An anti-CEA IgG was dosed at levels ranging from 5 to 500 pg in mice with xenografted LS174T
tumors. Mosaic images of full tumor cross sections that have been intensity scaled identically
are shown in Figure 2.3. Corresponding imaging of antigen expression in these tumor sections
confirms CEA expression throughout.
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Figure 2.3. Selected images of tumor sections from xenografts in mice administered between 5 and 500
pg of anti-CEA antibody sm3e labeled with Alexa Fluor 488 24 hours before sacrifice and tumor harvest.
Blue pseudocolor represents DAPI; green pseudocolor represents sm3e; red pseudocolor represents
blood vessels; not shown for clarity is antigen, which was also imaged in each section. Doses were 5, 15,
50, 150, and 500 pg in panels a-e, respectively. Note that low doses at 50 pg or less show clear
perivascular distribution, while higher doses of 150 pg and 500 pg appear to show complete saturation
of the tumor. All scale bars are 1 mm.
At low antibody doses, ranging from 5 pg to 50 pg, considerable perivascular binding and
localization of extravasated antibody is observed, with a general trend of increasing penetration
distance and perivascular antibody intensity with increased antibody dose (Figure 2.3 a-c). In
contrast, higher doses of 150 and 500 pg show near complete penetration of the tumor, with
no clear perivascular distribution of antibody. When tumor sections are analyzed by computer
to quantitatively determine microdistribution trends, doses of 5 and 15 pg are seen to display
perivascular distribution that then decreases to near background levels approximately 40-50
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pm from the blood vessels on average. In contrast, the 50 pg dose also shows enhanced
localization adjacent to blood vessels with decreasing signal with distance from vessels
beginning approximately 20 pm from the vessel, but this dose retains some degree of specific
signal and never drops to background levels. The highest two dose levels which appear to
saturate the tumor tissue show no perivascular localization. Essentially all tumor tissue is
reached, with marginal additional binding detectable between the 150 and 500 pg doses.
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Figure 2.4. Experimentally observed perivascular antibody:antigen distribution ratio as a function of
dose (a) and Krogh cylinder based predicted perivascular distribution of extravasated antibody (b). The
lower limit for signal in (a) was taken to be three standard deviations over the background signal.
Equations and paramaters used to generate panel (b) are detailed in Appendix A.
Microdistribution mathematical modeling
To predict how antibody penetration will depend on parameters such as antigen density and
endocytic half-life and antibody affinity, a previously described Krogh cylinder-based model was
extended (Appendix A)25. Parameter values were determined from the literature where
appropriate and from direct measurement in the case of the Krogh cylinder radius. This model
includes the effects of blood clearance, extravasation, antibody diffusion through the interstitial
space, binding, unbinding, and endocytic clearance. Simulations of single-vessel extravasated
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antibody profiles over the experimental dose range show excellent agreement with the
experimental results (Figure 2.4). These experimental results represent the averages of the
antibody microdistribution from thousands of blood vessels per tumor section analyzed. The
model reproduces the perivascular distribution seen at low doses, as well as the complete
penetration which occurs at the highest doses and the intermediate condition observed at the
50 pg dose level.
Thiele modulus analysis
For the LS174T tumor and the CEA-targeting sm3e antibody used in this study, tumor saturation
appears to occur at a dose between 50 and 150 pg. However, the dose required to saturate a
tumor will be dependent on several antibody- and antigen-dependent factors, including antigen
density and turnover rate as well as antibody affinity, permeability, diffusivity, and clearance
rate. For the case of IgGs, previous analyses have strongly suggested that the factors limiting
tumor penetration are not blood clearance related, but instead related to binding and
endocytosis of antibody-antigen complexes2. A dimensionless number termed the Thiele
modulus ($2) can be used to quantitatively describe the ratio of the rate of binding and
endocytosis of an antibody to its rate of extravasation and diffusion into the tumor. This rate of
extravasation and diffusion must be greater than the rate of binding and endocytosis (i.e., #2<
1 ) for the antibody to fully penetrate a given distance. Applying this dimensionless analysis
using parameters obtained from the literature or directly measured from experimental data
(Table 2.1) allows the determination of saturation criteria for a tumor as a function of antigen
density and turnover rate, parameters easily found in the literature or measured for a tumor
model of interest (Figure 2.5). Antibody affinity also can play a significant role, as very high
affinity antibodies bind essentially irreversibly to tumor antigen and are eventually endocytosed
and degraded.
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Figure 2.5. plots Of 4)2=1 trendlines as a function of bolus dose IgG injected and number of cell-surface
antigens per tumor cell, allowing for the estimation of minimum doses required for tumor saturation.
Data are plotted for a wide range of physiologically relevant antigen turnover rates. The shaded band
represents a typical range of constitutive turnover half-lives for membrane proteins. Parameters used in
model calculations are given in Table 2.1.
2.5 Discussion
We present here an unbiased image analysis of microdistribution of antibody and antigen in
xenograft tumors. The use of appropriately selected fluorophores allows the independent
imaging of extravasated antibodies, blood vessels, and antigen in entire xenograft tumor cross
sections. The full cross section, less any non-tumor or necrotic areas, can then be analyzed by
the use of a MATLAB program that measures and averages the pixel intensities in the antibody
and antigen channels for each of the blood vessels in a tumor section. These data represent a
snapshot of the average extravasated antibody distribution from all the vessels in an entire
tumor section. This two-dimensional cross section of a three dimensional tumor volume can be
treated as representative of the tumor volume because the thickness of the section is
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approximately 8 pm, which is a neglible distance relative to the typical diameter of the tumor
(5-10 mm).
Using this image analysis method, we determined that for the particular antigen and antibody
pair used here, complete tumor penetration occurs at a dose between 50 and 150 pg.
Quantitatively, perivascular distribution is clearly observed in low doses (5 and 15 pg), less
prominent at 50 pg, and absent at doses which fully penetrate the tumor. Interestingly, the
normalized antibody:antigen intensity changes relatively little between the highest dose levels,
suggesting that antigen saturation may have occurred and that increasing antibody dose
beyond this level has little potential beneficial effect on targeting tumor cells.
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Figure 2.6. Experimental measurement of Rkrogh in xenograft tumor tissue. Fraction of tissue vs. distance
from nearest blood vessel plotted at left for seven randomly selected tumors imaged. Right,
determination of median distance from nearest blood vessel for each section shown at left.
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A Krogh cylinder model of antibody distribution around a blood vessel was employed to predict
these results. This model uses parameters of the antibody and antigen that have been culled
from the recent literature, or measured from experimental results in the case of the Krogh
cylinder radius. This parameter was estimated directly from intervessel distribution data
measured in the tumor sections imaged (Figure 2.6). Using no fit parameters, the model shows
excellent agreement with the data. Despite the simplifications inherit in the use of the Krogh
cylinder model, the model is able to quantitatively predict the antibody distribution profiles
across the dose ranges examined. Low doses indicate an exclusively perivascular distribution,
moderate (50 pg) doses show enhanced binding near blood vessels but retain binding much
further from the vessel, and high doses show uniform antigen saturation. The model predicts
that the highest doses saturate all antigen binding sites; additional antibody accumulation at
these high doses is due to unbound antibody that has extravasated into the tumor and is free to
diffuse or bind free antigen. The experimental images may not capture this unbound antibody,
as during the tumor excision, embedding, sectioning, and immunofluorescent staining
processes there are abundant potential opportunities to wash away free antibody.
These concepts can be generalized to different antibody-antigen combinations through the use
of the Thiele modulus dimensionless quantity. This number, a ratio of the rate of binding and
catabolism to the rate of extravasation and diffusion, succinctly captures the limiting rate
processes for long serum half-life therapeutics like antibodies. It should be noted that
molecules with substantially shorter half-lives may also be limited by their rapid blood
clearance, although this is not the case for IgGs 2 . Setting the Thiele modulus equal to unity, at
which point the rates are equal, allows the determination of the minimum criteria for full
penetration of a tumor. These criteria will depend upon the easily measured quantities of
antigen density and endocytosis rate, as well as antibody properties. Typical antibody
properties are used for the plots in Figure 4 and listed in Table 1. The rate of antigen turnover
can be seen to have a very strong effect on tumor penetration, suggesting that antigens which
are endocytosed as a part of constitutive membrane turnover may be good targets with respect
to beneficial intratumoral distribution.
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Figure 2.7. CEA expression vs. distance from nearest vessel for 5 randomly selected tumor sections.
Examples are typical in that antigen expression is maintained at essentially constant levels through
distances of more than 100 pm from vessels, beyond which many of the cells are necrotic.
Antibody affinity may also play a significant role in tumor penetration; the criteria for
penetration of a 10 pM binder are markedly different from those of a 1 nM binder. This
phenomenon occurs as a consequence of the different time scales of unbinding for high versus
moderate affinity binders. High affinity binders rarely dissociate over the lifespan of bound
antigen, while moderate affinity binders are more likely to bind multiple antigens, diffusing
between each one. This may allow moderate affinity binders to penetrate farther into the
tumor than very high affinity binders, albeit at the cost of fewer antibodies per targeted cell.
This topic will be addressed in greater detail in Chapter 3.
Quantitative analysis and modeling of perivascular antibody distribution can be a useful
window into elucidating the factors which ultimately determine whether a given therapeutic is
able to fully penetrate tumor tissue. Experiments using a well characterized antibody-antigen
model system in vivo provide validation for the mathematical framework and show that tumor
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penetration should be possible at antibody doses near the high end of those commonly used in
preclinical studies. However, penetration is much easier to achieve for slowly internalizing
antigens such as those turned over constitutively with the cell membrane. Actively
endocytosed antigens require much larger doses for complete penetration; this is an important
consideration for antibody-drug conjugates, which are typically targeted to rapidly internalized
antigens. The pharmacodynamic benefits of efficient antibody-drug conjugate internalization
are obtained at the micropharmacokinetic cost of impeded tumor penetration.
Inefficient tumor penetration also has potential implications for the theory of tumor growth
based upon cancer stem cells (CSCs). There is evidence to suggest that these cells are
responsible for the generation of new cancer cells and ultimately the growth, differentiation,
and metastasis of tumors26. Under the CSC theory, it is paramount that the CSCs be targeted by
any potential therapeutic-if they are not killed, the tumor can be regenerated by the surviving
stem cells. However, there is also evidence to suggest that CSCs are often present in hypoxic
regions of the tumor which are far from blood vessels NEED TO FIND CITATIONS HERE. The CSC
theory of tumor growth suggests that penetration of therapeutics into hypoxic regions will be
necessary for the success of the treatment. This should be considered when choosing
therapeutic targets, as antigens with low endocytosis rates and moderate expression levels will
be more conducive to high tissue penetration. Another opportunity to target CSCs might lie in
determining antigens which are upregulated or selectively expressed on CSCs, thereby enabling
them to be targeted with no or reduced rates of endocytic consumption by normal (non-
proliferative) tumor cells located in perivascular regions. Such a strategy might then be
combined with "conventional" antibody therapy to eliminate CSCs and tumor cells in a single
step.
Consideration must be given to translating tumor penetration and antibody distribution data
obtained in preclinical animal models to the clinic. Xenograft models can be unreliable models
for preclinical drug efficacy experiments, and moreover morphogically xenograft tumors often
poorly resemble the primary tumors from which they were derived 27- 29 . There is limited
evidence that poor penetration of antibody therapeutics is observed in clinical cases.
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Compellingly, one of the studies most directly showing heterogeneous antibody distribution in
the clinic involves an antibody against the antigen A33, which has an extremely slow
endocytosis rate and as such is predicted to be a relatively "easy" tumor to penetrate 6 30'3'
Clinical studies of antibody therapeutics almost always show levels of accumulation of antibody
in the tumor as less than 0.1% injected dose/gram. In animal models, typical values are
approximately two orders of magnitude higher. This would argue that poor distribution see in
animal models would if anything understate the magnitude of the issue in human patients.
NOTE: This chapter was adapted from work previously published in Rhoden JJ and Wittrup
KD. Dose dependence of intratumoral perivascular distribution of monoclonal antibodies.
Journal of Pharmaceutical Sciences 101: 860-867 (2012).
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3. ANTIBODY AFFINITY VS. PENETRATION AND ACCUMULATION
3.1 Introduction
Poor penetration of therapeutic monoclonal antibodies has been well documented in
numerous preclinical models1- . Furthermore, there is some evidence that poor penetration of
these antibodies correlates with decreased therapeutic efficacy"' 1 . Most therapeutic
antibodies which target solid tumors are developed and engineered to have a high affinity for
their target antigen. This is thought to be beneficial for antibodies because high affinity
antibodies will bind strongly to their targets and remain bound for a longer period. Typical
therapeutic antibodies have affinities of single digit nanomolar or below, resulting in a typical
dissociation half-life of hours to days.
High affinity antibodies have been shown to exhibit a phenomenon in vivo that has been
termed the "binding site barrier". This phenomenon occurs exclusively with high affinity
antibodies, and is observed as a perivascular distribution of antibody therapeutics. Tumor cells
and tumor antigens near blood vessels are well targeted, but a few cell layers away from blood
vessels there are large areas which escape treatment. Over the last two decades, research has
shown that the "binding site barrier" is a consequence of many factors regulating the transport
of antibodies and other macromolecules into tumors2,8,12,14-16 . Antibodies are large molecules,
and consequently have slower diffusivity and vascular permeability than smaller molecules.
High affinity antibodies are unique in that they bind very tightly to their target antigens, and
this in turn means that they remain bound for a long time. In the context of solid tumors,
binding to antigen exposes the antibody to antigen-mediated clearance, and ultimately this has
been shown to be a major cause of the "binding site barrier" and perivascular distribution2,7,,14
Recent research on the binding characteristics of therapeutic antibodies, including the FDA-
approved antibodies cetuximab and trastuzumab, has shown that affinity can have a strong
influence on the distribution of antibodies in tumor tissue10 ,17 . High affinity antibodies at
moderate doses are localized to the perivascular space, while lower affinity antibodies
penetrate farther into the tumor tissue. However, as antibody affinity becomes lower, bulk
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tumor accumulation can decrease rapidly,2,18. We seek to study the effect of affinity on tumor
penetration and tumor accumulation in a quantitative fashion to determine whether there may
be an "optimal" affinity at which high tumor accumulation is achieved while maximizing tumor
penetration.
In the tumor space, high affinity antibodies tend to bind the first free antigen that they
encounter. Then, because they are high affinity, they will tend to remain bound for hours to
days. In contrast, moderate affinity antibodies might bind tumor antigen and remain bound for
a therapeutically relevant time period, but then unbind and have the opportunity to diffuse
farther into the tumor tissue. In this way, moderate affinity antibodies might sacrifice very high
binding in the perivascular region, while increasing penetration into tumor tissue farther form
blood vessels. This idea is illustrated schematically in Figure 3.1.
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Figure 3.1. Left, schematic illustration of the extravasation and binding of high affinity antibodies (top)
and moderate affinity antibodies (bottom). High affinity antibodies bind available antigen as they
diffuse from the blood vessel and usually have very long dissociation half lives, so they are often
internalized and degraded by the antigen they bind. Moderate affinity antibodies also bind available
antigen as they diffuse from the blood vessel, but have shorter dissociation half lives and will more often
unbind, continue to diffuse, and bind again until they are eventually endocytosed and degraded. At
right, illustration of the antigen binding characteristics that high affinity and moderate affinity antbodies
might exhibit around blood vessels. High affinity antibodies are expected to bind more antigen closer to
blood vessels, while moderate affinity antibodies are expected to have lowered antigen exposure in the
perivascular region while gaining access to tissue located farther from the blood vessels.
3.2 Materials and methods
Reagents
A low-picomolar humanized antibody to carcinoembryonic antigen (CEA), designated sm3e, has
previously been engineered and characterized19 . Another high affinity version of this antibody
which was isolated earlier in the directed evolution process, termed shMFE, was also used in
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this study. Both of these IgGs were used as the backbone to engineer monovalent constructs
consisting of the Fc domain and and scFv of the parent antibody, resulting in binding moieties
termed ds(Fv)-Fc's measuring approximately 79 kDa in size targeting the same epitope and
possessing similar pharmacokinetic properties as the parent IgGs 2. In addition, point mutants
of shMFE with mutations to single amino acids in the complementarity determining regions
were created and screened for changes in binding affinity. Several mutants were chosen for
further study based upon their decreased affinity to CEA. All antibodies and antibody
fragments were secreted in transiently transfected HEK 293 cells (Invitrogen, Carlsbad, CA),
purified by protein A resin (Millipore, Billerica, MA) and buffer exchanged into PBS. Anti-CEA
monoclonal antibody M85151a was purchased from Fitzgerald (Acton, MA) and goat anti-rat
546 and goat anti-human Fc antibody secondaries from Invitrogen. Antibody M85151a was
labeled with an Alexa Fluor 647 Protein Labeling kit and has been previously determined to be
noncompetitive with sm3e . Goat anti-human Fc antibody was labeled with an Alexa Fluor488
Protein Labeling kit.
Animal model
Animal use and care was conducted in full compliance and under approval from the MIT
Committee on Animal Care. A CEA-positive human colorectal cancer cell line, LS174T, was used
to induce xenograft formation in the flanks of 6-8 week old Ncr nude mice (Taconic, Hudson,
NY) by subcutaneous injection of 5 x 106 cancer cells. Tumors were allowed to establish and
grow to a size of 5-10 mm, at which point antibody injections were conducted. A 50 pg
(approximately 2 mg/kg) dose of antibody or antibody fragment was injected retroorbitally into
tumor bearing nude mice. Mice were sacrificed 24 hours after antibody administration, and
tumors were immediately excised and snap frozen in Optimal Cutting Temperature (OCT)
medium (Sakura Finetek USA, Torrance, CA) via isopentane over liquid nitrogen. Frozen blocks
were stored at -80*C until sectioned by the Koch Institute Histology Core Facility. Frozen blocks
were sectioned approximately 1-2 mm into the tumor tissue at a thickness of 8 pm and stored
at -80*C until stained and imaged.
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Immunofluorescence protocol
Frozen slides were first air dried for approximately 30 minutes, then tissue samples circled with
a PAP pen (Invitrogen, Carlsbad, CA). Tissues were fixed for 10 minutes at room temperature in
formalin, then washed 3 times with PBS. Blocking was performed with 5% goat serum
(Invitrogen) in PBS for 1 hour at room temp. Primary antibody incubation was 5% goat serum in
PBS + 1:100 rat anti-mouse CD31 (BD Pharmingen, San Diego, CA) overnight at 40C. Slides were
then washed three times with PBS, then incubated with PBS+0.1% Tween 20 (Sigma-Aldrich, St.
Louis, MO) + 1:200 goat anti-rat 546 (Invitrogen, Carlsbad, CA) + 1:100 M85151a-647 anti-CEA
antibody (Fitzgerald, Acton, MA) + 1:100 goat anti-human Fc-488 for 1 hour at room
temperature. Slides were washed 4 times with PBS, then mounted in Vectashield + DAPI
medium (Vector Labs, Burlingame, CA).
Fluorescence imaging
Slides were imaged using a DeltaVision Spectris microscope (Applied Precision, Issaquah, WA)
equipped with a motorized stage and running Softworx software (Applied Precision). Emission
and excitation filters were arranged to permit simultaneous 4-color imaging of DAPI, 488, 546,
and 647. The paneling feature of Softworx was used to capture the entire tumor section at a
resolution of 1.336 pm/pixel and to stitch together the fields into a single large mosaic image
for subsequent analysis.
Unbiased Image Analysis
Rather than introduce potential observer bias by manually selecting individual blood vessels for
analysis, images were analyzed as entire tumor sections for features including intervessel
distance, antibody penetration from blood vessels, and antigen distribution. The 546 nm (blood
vessel) plane was isolated, thresholded to include vessels only, and converted to a binary image
using ImageJ (NIH, Bethesda, MD). A Euclidean distance map was created from the vessel
binary, and this map was used as a mask to measure average intensity in the antibody (488) and
antigen (647) planes as a function of distance from nearest blood vessel by an automated
MATLAB (The Mathworks, Natick, MA) computer program. Regions of the tumor revealed to
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be necrotic or stromal tissue by examination of H&E staining or by absence of antigen were
excluded from the analysis.
Modeling
Antibody extravasation was modeled using an extension of a previously described Krogh
cylinder model of the tumor vasculature 2. A mathematical model, detailed in Appendix A,
was solved numerically in MATLAB (MathWorks, Natick, MA) using the method of lines and the
built-in numerical ordinary differential equation solver. Simulation results are reported as
fractional antigen saturation as defined below:
Fractional saturation= Antibody bound to tumor antigen+free antibody in tumor interstitium
Total tumor antigen
All simulation results were reported at a 24 hour time point to match experimental results. The
parameters which inform the model were all either directly measured or taken from the
literature. In the case of the diffusivity and vascular permeability of the novel monomeric
ds(Fv) antibody fragments, these parameters were estimated from fits of literature data
describing the effects of molecular size on these parameters 18
3.3 Results
High affinity anti-CEA antibodies and ds(Fv)-Fc derivatives
High-affinity anti-CEA antibodies and their monovalent derivatives were produced and purified
as previously described. The apparent affinities (bivalent for the IgGs, and monovalent for the
ds(Fv)s) against CEA expressing LS174T cells were measured, and results are summarized in
Figure 3.2.
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Figure 3.2. A, schematic representation of IgGs (sm3e and shMFE) and the ds(Fv)-Fc constructs derived
from them. The ds(Fv)s are approximately half the molecule weight and retain similar blood clearance
as the full IgGs due to the presence of intact Fc 2. B, apparent affinity of anti-CEA IgGs and ds(Fv)s
against fixed LS174T cells as measured by flow cytometry. Measured affinities are bivalent for the IgGs
and monovalent for their ds(Fv) derivatives. C, simulation predictions for all four constructs based upon
measured affinities and other parameters taken from the literature.
These anti-CEA antibodies were injected into LS174T tumor bearing mice at 50 pg, the tumors
excised and stained immunofluorescently as previously described. The full tumor cross sections
were imaged at high resolution and representative images scaled identically are shown in
Figure 3.3. The high affinity proteins (all except ds(shMFE)-Fc) all exhibit perivascular
distributions, with cells near blood vessels well targeted but leaving large areas of the tumor
untargeted. The substantially lower affinity ds(shMFE)-Fc has a much different distribution,
with much lower intensity, but much more homogeneous, antibody staining. There is little of
ds(Fv)
the perivascular distribution seen in the case of these tumors. However, the staining is
substantially above the background seen in mock (PBS) injected tumors, suggesting that the
observed staining derives from the presence of antibody.
Figure 3.3. A-C, sm3e IgG, ds(sm3e)-Fc, and shMFE IgG representative immunoflourescent images,
respectively. D, ds(shMFE)-Fc representative immunofluorescent image. All images were scaled
identically, and all scale bars are 1 mm. Large areas of unstained tissue in the interior regions of panels
A and C are necrotic regions as evidenced by H&E. Not shown for clarity is the antigen stain, which was
expressed uniformly throughout the viable tissue.
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IThe immunofluorescent images were processed as described previously to quantify the
distribution of the anti-CEA antbodies and constructs. The results of the unbiased image
analysis are shown in Figure 3.4. The three high affinity proteins, each of which possessed an
apparent Kd in vitro of less than 50 pM, are statistically indistinguishable from one another and
indicate a high level of antibody binding near blood vessels. The ds(shMFE)-Fc construct, in
contrast, is markedly different and shows a uniformly much lower degree of antibody binding,
consistent with the immunofluorescence imaging (Figure 3.3). To a distance of approximately
120 pm, beyond which there exists very little viable tissue (data not shown), all of the
constructs show a fairly homogeneous distribution with little dependence on distance from
nearest blood vessel.
Figure 3.4. Whole-section automated image analysis results. Antibody and antigen fluorescence signals
are quantitated and the antibody signal normalized to antigen signal. Error bars are ±S.D of analysis of 3-
5 tumors per construct.
Since there is very little viable tissue far from blood vessels, the data from whole tumor
sections is typically heavily weighted toward tissue near blood vessels. To better analyze
55
antibody penetration into tissue far from blood vessels, individual blood vessels isolated from
regions of low vascularity were found and analyzed to examine the penetration of the various
antibody constructs into the viable tissue surrounding these vessels. Approximately 5-8 such
vessels were identified and analyzed in 3-4 tumor sections per antibody construct, and the
results of the analysis of antibody distribution around these isolated vessels is shown in Figure
3.5. As indicated by the error bars, the distribution around blood vessels is highly variable.
However, just as in the case of the whole tumor sections, the high affinity antibodies are
indistinguishable from one another in their distribution and intensity, while the moderate
affinity ds(shMFE)-Fc is significantly lower intensity and more homogenous in its distribution.
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Figure 3.5. Left, high resolution image of isolated blood vessel surrounded by viable tumor tissue. Red
denotes blood vessels (CD31) and green anti-CEA antibody. Right, unbiased image analysis to quantitate
antibody distribution around isolated vessels. Error bars are ±S.D. and antibody signal is normalized to
antigen signal.
As a final method to analyze the distribution of these four antibody constructs, we sought to
evaluate the perceived distribution in whole tumor sections as rated by impartial and blinded
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human observers. Observers were asked to rate their perception of the heterogeneity or
homogeneity of antibody distribution on a five point scale. The observers were presented with
images processed to remove stromal and necrotic tissue and were not told in advance of the
purpose of the analysis. They were allowed to adjust the scaling of the antibody channel to
better examine the images. Results are shown in Figure 3.6. As in the previous analyses,
observers were unable to distinguish between the high affinity antibodies and rated them all
highly heterogeneous at approximately a 4 on a 5 point scale. They rated the moderate affinity
antibody differently and much more homogeneously, at approximately a 2 on a 5 point scale.
Subjective heterogeneity rating
(1=homogeneous, 5=very heterogeneous)
5
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Figure 3.6. Left, representative processed image shown to blinded and impartial observers for subjective
heterogeneity rating. Observers were asked to rate heterogeneity of the antibody signal (green) on a
five point scale. Right, results from n=4 observers. Error bars are ±S.D.
shMFE affinity series
To better study the range of antibody affinities in the "moderate" range of single and double
digit nanomolar, a set of point mutants of the shMFE high affinity (~50 pM) antibody was
generated and tested for binding to CEA expressing cells, resulting in the selection of a set of
anti-CEA binders with affinities spanning over three orders of magnitude (Table 3.1).
Importantly, all five antibodies are full length human IgG1 isotype antibodies, and all have a
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common heritage through the affinity maturation of parent antibody MFE 1924. As a result, they
are expected to be very similar molecules biochemically and also behave similar in their in vivo
pharmacokinetics.
a-CEA antibody affinity series
derived from common parent
Sm3e ~10 pM
shMFE ~50 pM
shMFE-F -2nM
shMFE-L ~20 nM
shMFE-T ~30 nM
Table 3.1. Apparent (bivalent) affinities of anti-CEA antibodies on CEA-expressing fixed tumor cells as
measured by flow cytometry. Sm3e is an affinity-matured derivative of shMFE, and shMFE was
subjected to selective point mutations in the complementarity determining region to generate
moderate affinity shMFE-F, -L, and -T antibodies.
This affinity series of antibodies was injected into nude mice bearing LS174T tumors, allowed to
circulate for 24 hours, and the tumor excised, sectioned, and stained for immunofluorescence
as previously described. Whole tumor sections were then imaged at high resolution, stitched
together into a large mosaic image, and processed using the unbiased image analysis and
quantitation tools described earlier. Representative immunofluorescent images are shown in
Figure 3.7.
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Figure 3.7. Representative immunoflourescent images of tumor sections dosed with shMFE or various
lower affinity point mutants of shMFE. For clarity, only antibody signal is shown (green). Cross-hatching
is an artifact resulting from the microscopy process. All sections measure 5-10 mm across.
As antibody signals were much lower than anticipated for the shMFE point mutants, a
biodistribution study was conducted by collaborators at Beth Israel Deaconness Medical Center
(BIDMC). All five anti-CEA antibodies were labeled with a radioactive marker, dosed into tumor
bearing mice, and the organs removed 24 hours following antibody dosing for determination of
the antibody signal in each organ. These data are presented in Figure 3.8. By comparing the
antigen positive (LS174T) and antigen negative (c6) tumors, it is possible to determine the
signal that results from specific accumulation due to antigen binding and the amount that
accumulates nonspecifically. The subnanomolar binders, sm3e and shMFE, both show strong
accumulation in the antigen-positive tumor over the antigen-negative tumor, indicating
binding-mediated retention and accumulation. In contrast, all three lower affinity shMFE point
mutants show approximately equal binding in the antigen-positive and antigen-negative
tumors, indicating that binding is unlikely to be a major contributor to enhancing tumor
accumulation. This agrees with the immunofluorescence data, which was also unable to detect
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significant binding in the tumor in the case of the shMFE point mutants, but showed strong
specific binding of shMFE and sm3e.
IgG and Fc 24 h Biodistribution
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Figure 3.8. Biodistribution data, courtesy of Kelly Orcutt and taken at BIDMC, shows that subnanomolar
affinity binders accumulate specifically in antigen-positive tumors versus antigen-negative tumors at the
24 h time point. Weaker binders show equivalent accumulation regardless of the presence or absence
of antigen, indicating that antigen-mediated antibody accumulation is not a major contributor with
these antibodies.
3.4 Discussion
Two separate experiments were conducted, both using antibodies or antibody fragments
directed against CEA. In both cases, subnanomolar affinity binders exhibited quantitatively and
qualitatively different microdistribution and tumor accumulation characteristics than did
nanomolar or weaker affinity binders. High affinity antibodies, such as sm3e (~10 pM) and
shMFE (~50 pM) both showed perivascular distribution which is characteristic of high affinity
antibodies given at subsaturating dosesi 7,25. These high affinity antibodies were all less than
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100 pM binding affinity, and experimentally were indistinguishable from one another. This is
not surprising, as high affinity antibodies in this range of Kd values are predicted to have very
similar perivascular distributions (Figure 3.2C). Examination of the experimental data in Figure
3.4 also shows that whole tumor section microdistribution data can be heterogeneous, as could
be expected given the heterogeneity inherit in the tumor microenvironment.
The moderate affinity antibodies were expected to show a qualitatively and quantitatively
different distribution in the tumor (Figure 3.2). These antibodies, because they are more likely
at any given time to unbind antigen and be free to diffuse through tumor tissue, were expected
to penetrate farther into the tumor tissue at the expense of maximizing antigen binding in
regions proximal to blood vessels. Experimentally, the moderate affinity (2-30 nM) antibodies
showed a much more homogeneous distribution through the tissue and little dependence on
distance from blood vessels. Mathematical modeling (Figure 3.2) suggested this general trend,
but seems to have underestimated the degree to which the phenomenon occurs. Extending
the modeling to weaker affinity antibodies offers a more complete picture as depicted in Figure
3.9. From Figure 3.9A, we see that antibodies around 1-10 nM are predicted to lose a great
deal of their perivascular distribution and transition to a more homogeneous distribution
without a strong dependence on distance from blood vessels. At very low affinities, there
appears to be no such dependence and much of the antibody in the tumor is retained
nonspecifically as free (unbound) antibody. This appears to be the situation encountered with
the shMFE point mutants, which at moderate affinities lost perivascular dependence and
showed little to no antigen-mediated retention in the tumor (Figure 3.8). In Figure 3.9B, we see
the effect of antibody affinity and desired receptor occupancy on the predicted penetration
distance. For high receptor occupancy, it is necessary to have a high affinity antibody that
remains bound to cells near the bloods vessel that are bound as the antibody extravasates.
However, as receptor occupancy decreases, distance penetrated into the tumor increases
dramatically. It can also be seen that there may be some benefit to moderate affinity in terms
of penetration distance. The 0.1 fractional receptor occupancy curve shows enhanced
penetration in the single digit nanomolar range relative to any other affinity. However, it
should be noted for all occupancy levels that the decrease in penetration distance as affinity
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decreases past a certain point is extremely rapid, and so slightly weaker than expected affinities
can result in a complete failure to achieve a desired receptor occupancy.
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Figure 39. A modeling results of penetration from blood vessels as a function of antibody affinity.
Simulation results span from 10 pM to 100 nM, a range which includes the vast majority of antibodies.
B, predicted penetration distance of antibodies as a function of affinity and receptor occupancy. Lines
represent receptor occupancy (fraction of available antigen bound by antibody).
As can be seen in Figure 3.9, modeling predicts that moderate affinity antibodies penetrate
farther into the tumor. Experimentally, this phenomenon was rarely observed, although it was
seen, for example as shown in Figure 3.10. Both modeling and experiment agree that any
enhanced penetration of moderate affinity antibodies would only be seen at relatively far
distances from blood vessels-approximately 100 pm or more. In practice, very little viable
tissue exists so far from blood vessels, largely because the diffusion limit of oxygen through
tissue is thought to be just beyond this limit 26 However, there is evidence to suggest that
these isolated regions may harbor tumor stem cells, which are known to be resistant to hypoxia
and are able to regenerate the tumor if not killed themselves 27,28 In an attempt to examine
these regions, isolated vessels supplying tissue farther than 100 pm were identified and
analyzed for their perivascular distribution characteristics (Figure 3.5). However, there were
few differences found among the high affinity antibodies, and the moderate affinity antibodies
distributed well but with relatively low binding.
The predicted distributions for the moderate affinity antibodies (Figures 3.2 and 3.9) were not
seen experimentally. Instead, a distribution more similar to a much weaker affinity antibody,
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such as a 100 nM affinity antibody (Figure 3.9) was observed. The cause of this may be that the
affinity of all antibody constructs was measured in vitro on fixed cells. This environment is
much different than the tumor interstitium in which the antibodies were binding in the in vivo
experiments, and it seems reasonable that the apparent affinity might be lower in such a
complex environment with many other competing molecules. Therefore, an antibody
measured at a relatively high affinity in vitro might behave as a lower affinity antibody in vivo.
Although enhanced penetration at distances far from tumor vessels was observed in some
isolated instances (Figure 3.10), generally the distribution was split between high affinity (100
pM or better) antibodies and lower affinity (single digit nanomolar or higher) antibodies, each
of which were indistinguishable from one another. Little evidence of intermediate behavior,
i.e. of somewhat enhanced penetration while retaining a high degree of antigen binding, was
observed. Insights into the cause of this behavior come from mathematical modeling and data
from the literature (Figure 3.10). This analysis suggests that the "window" for enhanced tumor
penetration spans only a small affinity range of less than an order of magnitude. In this
window, penetration can be enhanced by a distance of approximately a cell layer or slightly
more. However, as shown in Figure 3.10, this window of enhanced penetration is also very
close to the "cliff" of greatly decreased tumor accumulation. So, although there are marginal
potential gains to be made in a certain moderate affinity range, this range is quite narrow.
Moreover, this range is positioned on the edge of a "cliff" beyond which accumulation of
antibody in the tumor decreases dramatically.
This observation has significant implications for therapeutic applications. Depending upon the
mechanism of action, high antigen saturation may be important or critical-for example, a
monoclonal antibody which exerts an effect by blocking ligand binding. Other mechanisms may
require only very small amounts of antigen binding, such as very potent immunotoxins or some
radioimmunotherapies. These different mechanisms of action call for substantially different
criteria for tumor penetration and fractional antigen saturation. This research may have
implications for the development of antibody-based therapeutics in many different indications
and disease types.
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Figure 3.10. A, example of one experiment in which a moderate affinity (~5 nM Kd, shown in green)
antibody was shown to penetrate farther into tumor tissue than high affinity antibodies. Note that the
moderate affinity antibody has a lower signal at the blood vessel, but higher signal far from the blood
vessel. B, plot of antibody penetration (defined as the maximum distance at which 50% receptor
occupancy is retained at 24 hours post-injection) and bulk uptake of antibody (normalized to maximum
uptake at 24 hours) vs. antibody affinity. Shaded red is the zone of moderate affinity in which enhanced
tumor penetration may be achieved. Note that this region is very close to a rapid decrease in bulk
uptake with weakening affinity. C, plot adapted from 18 and showing theoretical (solid line) and data
from the literature (points) illustrating the decrease in tumor uptake of antibodies with decreasing
affinity. These data and modeling agree well with panel B.
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4. ANTIBODY DOSING STRATEGIES TO IMPROVE TUMOR PENETRATION
4.1 Introduction
Poor penetration of monoclonal antibodies into tumor tissue in preclinical animal models of
cancer has been well documented for many antibodies, antigens, and tumor types 1-1. The
studies which have shown poor penetration into solid tumors typically consist of a single
intravenous or intraperitoneal injection of the antibody of interest, followed by a waiting period
of hours to days to allow the antibody to circulate and extravasate, and finally evaluation of the
distribution of the antibody at the desired time point. In the clinic, however, antibody
treatments are typically not administered as a single bolus dose. Instead, multiple infusions are
given spaced out over weeks to months. This strategy has been necessary for many cancer
treatments, most notably chemotherapy, because the therapeutic is itself toxic and so periods
of time between doses are necessary to allow healthy tissue to recover. Antibodies similarly
often have some degree of toxicity in vivo and are therefore administered in multiple doses
separated by waiting periods to allow healthy tissue to recover.
Clinical studies of doses and dosing strategies for therapeutic monoclonal antibodies illustrate
this dosing strategy. For instance, a phase 11 clinical trial of FDA-approved monoclonal antibody
cetuximab in patients with colorectal cancer involved weekly i.v. infusions of antibody . A
phase Ill trial of trastuzumab, another FDA approved antibody, for metastatic breast cancer
involved 6 cycles of weekly i.v. infusions of a the drug'3 .
The in vivo tissue distribution of multiple doses of antibodies in dosing strategies similar to the
clinical situation has not been well studied. These strategies raise new issues that are not
important for single-dose studies, namely in that the therapeutic antibodies are likely to exert a
pharmacodynamic effect on the tumor in these studies. Many therapeutic antibodies have
been shown to delay or shrink tumors in animal models, and others have been shown to alter
antigen expression or catabolism 2,14 ,15 . Antigen expression and turnover rate have been shown
to be important parameters in determining the penetration and catabolism of antibodies in
tumors 5''10'16. The effects of tumor cell killing also complicate the picture, adding additional
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rates to consider in the rate at which tumor cells are killed and the rate in which tumors are
repopulated and grow.
One possible outcome of serial dosing of therapeutic antibodies is to progressively penetrate
farther into the tumor, killing tumor cells layer-by-layer with successive doses. This idea is
illustrated schematically in Figure 4.1. This hypothesis seems likely to occur if the rate of
antibody-mediated cell killing is more rapid than the rate of tumor cell growth. However, if
tumor cells grow more rapidly than they can be killed, then this strategy may succeed in
slowing the growth of the tumor, but will not shrink or eliminate the tumor. Further
complicating matters is the possibility of other physiological changes brought about by multiple
dosing strategies, such as dead tumor cell "debris" impeding transport in tumors, or the
possibility of developing resistance to therapy over the longer time periods of these dosing
17-19strategies
Figure 4.1. Schematic illustration of a multiple dosing strategy on the distribution of a therapeutic
antibody around a blood vessel. The red circle in the center represents a tumor vessel, and the green
region surrounding it represents the region penetrated by a therapeutic antibody. Successive doses
penetrate farther and farther from the vessel as perivascular tumor cells are killed off, as represented by
the concentric dashed circles.
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4.2 Materials and methods
Reagents
A trispecific EGFR binding protein based upon the backbone of antibody 225, which is in clinical
use as cetuximab, has been previously generated and characterized and was termed HN-D/LC-A
. This antibody as well as parental 225 antibody were secreted in transiently transfected HEK
293 cells (Invitrogen, Carlsbad, CA), purified by protein A resin (Millipore, Billerica, MA) and
buffer exchanged into PBS. Goat anti-rat 546 and goat anti-human Fc antibody secondary
antibodies were purchased from Invitrogen (Carlsbad, CA). The anti-human Fc secondary
antibody was labeled with an Alexa Fluor 488 Protein Labeling kit (Invitrogen). Aliquots of HN-
D/LC-A were labeled with Alexa Fluor 488 or 647 protein labeling kits.
Animal model
Animal use and care was conducted in full compliance and under approval from the MIT
Committee on Animal Care. En EGFR-positive human colorectal cancer cell line, HCT-116, was
used to induce xenograft formation in the flanks of 6-8 week old Ncr nude mice (Taconic,
Hudson, NY) by subcutaneous injection of 5 x 106 cancer cells. Tumors were allowed to
establish and grow for one week, at which point antibody injections were conducted at
schedules and doses detailed in the Results section. Tumors were measured daily and volume
calculated as L2 xW/2. All injections were conducted retroorbitally, alternating eyes between
injections, except in the case of daily injections which were rotated between the eyes and each
of the two veins in the tail (four sites total). The penultimate antibody injection was labeled
with Alexa Fluor 647, and the final antibody injection was labeled with Alexa Fluor 488. Mice
were sacrificed 24 hours after the final antibody administration, and tumors were immediately
excised, cut in half with a razor blade, and one half snap frozen in Optimal Cutting Temperature
(OCT) medium (Sakura Finetek USA, Torrance, CA) via isopentane over liquid nitrogen. Frozen
blocks were stored at -80*C until sectioned by the Koch Institute Histology Core Facility. Frozen
blocks were sectioned approximately 1-2 mm into the tumor tissue at a thickness of 8 pm and
stored at -800C until stained and imaged.
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Tumor dissociation andflow cytometry
One half of each freshly excised tumor was finely diced with a razor. The diced tumor was
digested in 2 ml digest medium consisting of 1 mg/ml collagenase A (Roche, Indianapolis, IN)
and 105 units/mI DNAse I (Roche) in RPMI medium (American Type Culture Collection,
Manassas, VA) for 45 minutes at 37*C. The digestion was quenched by the addition of 0.5 ml
fetal bovine serum (Invitrogen) and passed through a cell strainer (BD Biosciences, San Jose,
CA). Cells were washed with sterile phosphate buffered saline (PBS, Invitrogen) and red blood
cells were lysed for 5 minutes in 5 ml lysis buffer composed of 8.26 g ammonium chloride, 1 g
potassium bicarbonate, and 0.037 EDTA per liter of water. Lysis was quenched with 45 ml PBS,
cells spun down, and then resuspended and stained for flow cytometry. For flow cytometric
analysis, cells were incubated with fluorescently labeled antibodies, including PE anti-human
HLA-A2 (BioLegend, San Diego, CA) to distinguish human cells and propidium iodide (Sigma
Aldrich, St Louis, MO) for live/dead analysis. Cells were washed with PBS, then run on flow
cytometry using an Accuri c6 cytometer (BD Biosciences) and 4 color detection.
Immunofluorescence protocol
Frozen slides were first air dried for approximately 30 minutes, then tissue samples circled with
a PAP pen (Invitrogen, Carlsbad, CA). Tissues were fixed for 10 minutes at room temperature in
formalin, then washed 3 times with PBS. Blocking was performed with 5% goat serum
(Invitrogen) in PBS for 1 hour at room temp. Primary antibody incubation was 5% goat serum in
PBS + 1:100 rat anti-mouse CD31 (BD Pharmingen, San Diego, CA) overnight at 4*C. Slides were
then washed three times with PBS, then incubated with PBS+0.1% Tween 20 (Sigma-Aldrich, St.
Louis, MO) + 1:200 goat anti-rat 546 (Invitrogen, Carlsbad, CA) + 1:100 goat anti-human Fc 488
antibody for 1 hour at room temperature. Slides were washed 4 times with PBS, then mounted
in Vectashield + DAPI medium (Vector Labs, Burlingame, CA).
Fluorescence imaging
Slides were imaged using a DeltaVision Spectris microscope (Applied Precision, Issaquah, WA)
equipped with a motorized stage and running Softworx software (Applied Precision). Emission
70
and excitation filters were arranged to permit simultaneous 4-color imaging of DAPI, 488, 546,
and 647. The paneling feature of Softworx was used to capture the entire tumor section at a
resolution of 1.336 pm/pixel and to stitch together the fields into a single large mosaic image
for subsequent analysis.
Unbiased Image Analysis
Rather than introduce potential observer bias by manually selecting individual blood vessels for
analysis, images were analyzed as entire tumor sections for features including intervessel
distance, antibody penetration from blood vessels, and antigen distribution. The 546 nm (blood
vessel) plane was isolated, thresholded to include vessels only, and converted to a binary image
using ImageJ (NIH, Bethesda, MD). A Euclidean distance map was created from the vessel
binary, and this map was used as a mask to measure average intensity in the antibody (488 and/or
647) plane as a function of distance from nearest blood vessel by an automated MATLAB (The
Mathworks, Natick, MA) computer program. Regions of the tumor revealed to be necrotic or
stromal tissue by examination of H&E staining or by absence of antigen were excluded from the
analysis.
Modeling
Antibody extravasation was modeled using an extension of a previously described Krogh
cylinder model of the tumor vasculature 20,21. A mathematical model, detailed in Appendix A,
was solved numerically in MATLAB (MathWorks, Natick, MA) using the method of lines and the
built-in numerical ordinary differential equation solver. Simulation results are reported as
fractional antigen saturation as defined below:
Fractional saturation= Antibody bound to tumor antigen+free antibody in tumor interstitium
Total tumor antigen
All simulation results were reported at a 24 hour time point to match experimental results. The
parameters which inform the model were all either directly measured or taken from the
literature (Appendix A).
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4.3 Results
To compare varying dosing strategies of a therapeutic antibody, an experiment was devised to
administer the EGFR-targeted trispecific antibody HN-D/LC-A via three different dosing
regimens in a mouse xenograft model of cancer. This antibody was administered to mice
bearing HCT-116 colorectal cancer xenografts, a model in which EGFR was previously shown to
be downregulated by HN-D/LC-A 14. Antibody treatment was carried out in three treatment
groups as shown in Figure 4.2, plus a PBS vehicle control group. A fixed dose of 300 pg of HN-
D/LC-A weekly was administered, split into either a single weekly bolus dose, twice weekly
doses, or daily doses of only 43 pg. Tumor growth was monitored regularly throughout the
treatment period of five weeks. The penultimate dose of antibody was labeled with Alexa Fluor
647 fluorescent dye, and the final dose at 24 hours before euthanasia was labeled with Alexa
Fluor 488 fluorescent dye.
300 pg weekly
150 pig 2x weekly
43 pg dailv
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Figure 4.2. Illustration of HN-D/LC-A dosing schedule. Top, 300 pg dose given weekly. Middle, 150 pg
dose given twice weekly. Bottom, 43 pg dose given daily. All doses sum to 300 pg total weekly dose.
Arrows indicate doses; red arrows indicate 647-labeled HN-D/LC-A doses, and green arrows represent
488-labeled doses. All mice were sacrificed 24 hours following administration of the last dose (488-
labeled dose).
Modeling of expected plasma concentrations of HN-D/LC-A and tumor penetration profiles
based upon a Krogh cylinder model were carried out concurrently with the in vivo experiment.
The results of these simulation are shown in Figure 4.3. In the case of weekly and twice weekly
HN-D/LC-A injections, tumor plasma concentrations change little from dose to dose. In general,
there is a spike around the time of the injection, then a rapid decline in plasma concentrations
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to a fraction of the peak. The pattern repeats with each dose, with a marginal increase in
maximal plasma concentrations with the first few doses. In contrast, the daily dosing schedule
displays the same peak-to-valley distribution, but with a marked change in the average plasma
concentration of the therapeutic during the first few doses. The first 3-5 doses show a gradual
increase in plasma concentration until achieving an apparent plateau approximately one week
after beginning dosing.
The predicted distribution of the therapeutics around blood vessels also shows a distinct profile
dependent upon the dosing regimen. In the case of daily injections, the radius of targeted
tissue increases with time and number of doses, plateauing after approximately a week. Twice
weekly and weekly dosing strategies shown less of a dependence on time, presumably because
the plasma concentrations with time are little changed over repeated doses. Interestingly,
these more widely spaced doses show the effects of antigen-mediated endocytosis (Figure 4.3
weekly dosing). In this case, the distribution between doses is markedly different than the
distribution immediately following doses. Between doses, because relatively little HN-D/LC-A is
available in the circulation, antigen-mediated catabolism dominates and markedly reduces the
penetration of extravasated HN-D/LC-A into the tumor tissue. This effect is seen less in the
case of twice weekly dosing and very little in the case of daily dosing because plasma drug
concentrations are maintained at higher levels.
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Figure 4.3. Simulated plasma concentration (left column) and perivascular distribution profile at
different time points (right column). Top, daily dosing; middle, twice weekly dosing; bottom, weekly
dosing. All dosing strategies administered 300 ptg of HN-D/LC-A per weekly period.
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Tumor growth was highly heterogeneous, as shown in Figure 4.4. Average tumor sizes never
significantly diverged from one another throughout the five weeks of treatment, and all three
treatment groups were statistically indistinguishable from one another and the PBS control
group at the end of the treatment cycle. Examination of the individual tumor growth curves
gives some insights into the growth characteristics of the tumors. Two tumors grew much
more rapidly than the rest of the tumors, and several tumors, including two in the twice weekly
treatment group, were quite well controlled and in one case complete remission was achieved.
The majority of the tumors grew at a similar, gradual pace during antibody treatment.
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Figure 4.4. Growth of xenograft tumors. Average tumor sizes (error bars ±S.E.) are shown at left, and
individual tumor curves are shown at right. Tumor were measured by calipers daily and volumes
estimated by L2xW/2.
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Upon reaching the end of five weeks of antibody treatment, the mice were sacrificed and the
tumors excised for analysis. Each tumor was cut in half, and one of these halves was
dissociated and stained for human cells by human HLA antibody and viability by propidium
iodide. Four color flow cytometry also allowed the collection of fluorescence data
corresponding to the Alexa Fluor 488 and 647 labeled therapeutic antibodies. Several thousand
cells were collected for each of seven mice, and the results of the flow cytometric analysis of
these mice are shown in Figure 4.5. In the case of both fluorophores, no apparent signal could
be observed. The PBS control mice, which received no antibody, were indistinguishable from
each of the three treatment groups. This was the case for not only the penultimate dose of
647-labeled protein (Figure 4.5, right) but also the last dose of 488-labeled protein which was
administered 24 hours prior to euthanasia for all mice.
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Figure 4.5. Flow cytometric analysis of dissociated tumor xenografts freshly excised from the flanks of
tumor-bearing mice. The penultimate antibody dose was labeled with Alexa Fluor 647 (cytometry gate
FL4) and the last dose of antibody, administered 24 hours prior to tumor excision, was labeled with
Alexa Fluor 488. At left, results of 7 mice, at least one from each treatment group, in the FLI channel.
At right, results of the same 7 mice in the FL4 channel. Gating was done on human HLA-positive cells
which were viable by PI staining.
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The second half of each tumor was flash frozen, sectioned, and immunofluorescently stained
for DAPI and CD31. These tumors were examined using a fluorescence microscope. At low
magnification, little evidence of the 488 or 647 signals corresponding to the last and
penultimate HN-D/LC-A doses was present. However, at high magnification, evidence of both
fluorophores became apparent as shown in Figure 4.6. In particular, the last dose which was
labeled with Alexa Fluor 488 could clearly be seen and was distributed in a punctate manner
which has previously been documented for this EGFR trispecific antibody14 . The 647-labeled
dose, which was administered 48 hours to 8 days prior to euthanasia, depending on the dosing
scheme, was occasionally observed but was markedly less intense as well as less widely
distributed. The antibody signal could only be observed at an appreciable signal when
magnified 40x or greater, and since this magnification would require many thousands of
individual panels to be stitched together to reconstitute the entire tumor, it was not
computationally feasible to image the entire tumor for paneling. Instead, multiple regions of
apparent antibody signal were acquired for each tumor for subsequent analysis and
quantitation of antibody signal and localization.
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Figure 4.6. Representative high-magnification immunofluorescent images of HCT-116 xenograft tumor
sections. DAPI and CD31 staining were clear and consistent throughout the tumor. Evidence of the last
antibody dosed appears in the 488 channel, where the antibody can be observed distributed around
perfused blood vessels and clustered into punctate spots around cell membranes. The penultimate
antibody dose was 647 labeled and was administered 2 days prior to euthasia (daily dosing), 4 days prior
to euthanasia (twice weekly dosing), or 8 days prior to euthanasia (weekly dosing).
Adding to the complications for immunofluorescent imaging of the HCT-116 was the unusual
distribution of viable tumor tissue in the tumor sections. Examination of H&E sections from
these tumors reveals a serpiginous distribution of necrotic tissue in these sections, regardless of
treatment schedule or size of the tumor (Figure 4.7). Around much of the periphery of the
tumor and throughout the interior of the tumor in small "islands" around blood vessels are
pockets of viable tumor tissue. However, they are often surrounded by necrotic tissue, making
analysis of large regions of the tumor difficult because these large regions tend to be composed
largely of dead tissue.
78
DAPI
Figure 4.7. Representative H&E images of tumor sections from all four treatment groups. Lighter purple
areas are viable tumor cells and tend to be localized in all sections around the periphery of the tumor
and in small pockets in the interior of the tumor. Pink to red regions surrounding these viable pockets
are regions of necrotic tissue.
This complication, along with the observation that 488 and 647 antibody signals corresponding
to the injected antibody were quite low and only visible at high magnification, led to the
decision to visualize injected antibody with an anti-human Fc secondary antibody. Using this
secondary antibody dramatically increases the immunofluorescent signal corresponding to the
injected antibody (Figure 4.8) at the cost of the loss of the ability to distinguish the last dose
and penultimate dose from one another. In addition, because viable tumor tissue was only
present in small pockets throughout the tumor, vessels were isolated for analysis on a vessel-
by-vessel basis with 5-12 representative vessels chosen from each tumor section for analysis as
depicted in Figure 4.8.
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Figure 4.8. Representative immunofluorescent images and data analysis using anti-human Fc-488
secondary antibody to visualize injected HN-D/LC-A antibody. At left, low magnification (10x) image of
DAPI (blue), HN-D/LC-A (green), and CD31 (red). Middle, image of a representative vessel chosen for
subsequent image analysis and quantitation. Green represents extravasated antibody, and red CD31.
Right, example of analysis of antibody intensity and perivascular localization in several such vessels.
Analysis of the images of single vessels in many different tumor sections is depicted in Figure
4.9. It can clearly be seen that substantial heterogeneity exists from section to section, even
within each treatment group. In most tumors, antibody intensity shows a modest dependence
on proximity to nearest vessel, although there are a few tumors which do not. All tumors show
enhanced antibody signal near blood vessels relative to PBS controls and stromal tissue. In this
study, stromal tissue comes from one tumor that was controlled by treatment (Figure 4.4) and
was revealed to be scar tissue upon tumor excision. Maximum antibody intensity and decrease
in intensity with distance are highly variable through the sections.
On average (Figure 4.9), the antibody intensity profiles in the three treatment groups follow
very similar patterns. There is a perivascular localization of antibody, with highest signal
nearest the blood vessel and a decrease in signal through approximately 100 Pm. There is no
statistical difference between the treatment groups, although all three are substantially
different than the PBS cohort or the stromal tissue.
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Figure 4.9. Top, antibody intensity vs. distance from nearest vessel for each tumor analyzed. Curves
represent averages of 5-12 vessels per tumor. Bottom, average of all vessels for each treatment group.
Nontumor tissue refers to scar tissue found in place of tumor in a mouse which experienced complete
tumor regression. Error bars not shown for clarity. No significant difference was observed between
treatment groups.
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4.4 Discussion
We present here a study of efficacy and intratumor microdistribution of therapeutic
monoclonal antibodies administered through several different dosing strategies. A fixed weekly
quantity of a trispecific anti-EGFR antibody was dosed either weekly, twice weekly, or daily for a
five week course of treatment of mice bearing xenograft tumors shown to be sensitive to the
treatment in vitro. Tumor growth inhibition was monitored during the treatment regimen, and
following treatment the remaining tumors were resected, sectioned, and quantitatively
analyzed for levels and perivascular localization characteristics of the extravasated and bound
antibody in the tumor sections. Through these studies, we sought to correlate any observed
differences in tumor control with the degree to which the antibody therapeutics were able to
penetrate the tumor tissue.
The tumor growth inhibition part of the study demonstrated a great deal of heterogeneity in
the growth rate of the tumors regardless of treatment group or schedule. Some tumors grew
quite rapidly, while others grew gradually. No significant difference in tumor growth rate was
observed between groups or relative to PBS-treated control mice. Although not statistically
significant, it is interesting to note that four of the five smallest tumors at the conclusion of the
study, including the only tumor to regress completely, belonged to the weekly or biweekly
treatment groups, which also received the largest bolus doses of antibody. The heterogeneity
in tumor growth makes it difficult to draw conclusions and appears to be somewhat random.
For instance, as shown in Figure 4.10, the size of the tumor at the start of treatment (day 10) is
strongly correlated with the size at after nearly 4 weeks of treatment, regardless of treatment
regimen.
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Figure 4.10. Tumor volume measured near the start of treatment (day 10) vs. the size of the tumor after
3.5 weeks of HN-D/LC-A treatment (day 35). Regardless of treatment group or schedule, the size of the
tumor at day 35 is correlated with its size at the start of treatment.
The results of the analysis of antibody penetration into tumor tissue indicate that tumor
penetration was not significantly different between the tumor groups. Efforts to use flow
cytometry to quantify the fraction of tumor cells targeted by antibody failed. This likely
occurred because the process used to dissociate the tumor involves proteolytic enzymes to
separate tumor cells which may also have dissociated the bound antibody from the cells. It is
possible that a more mild dissociation protocol may have given different results. However,
frozen tumor sections retained bound antibody and were amenable to immunofluorescent
imaging and study. Weak signal could be observed from the last two doses of fluorescently
labeled antibody administered to the mice in some cases. However, the signal was weak and
only readily observable under high magnification. We hypothesize that the signal was weak
because EGFR is a very rapidly internalized and degraded antigen, especially when targeted by
HN-D/LC-A . It seems plausible that the 24 hour period between the last antibody dose and
collection of the tumor was enough time for a substantial quantity of the antibody to be
degraded, reducing the signal to the degree observed.
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To enhance the signal of the bound HN-D/LC-A, a secondary antibody was used, resulting in the
loss of the ability to distinguish between the penultimate and final antibody doses, but
dramatically increasing the immunofluorescent signal to a level more amenable to imaging
large regions of the tumor for subsequent quantitative analysis. Tumors were imaged in this
manner and stitched together to be analyzed for quantitation of antibody distribution around
blood vessels. However, examination of H&E sections of adjacent tumor tissue revealed that
~70-80% of the tumor was necrotic, regardless of treatment schedule (Figure 4.7). Moreover,
the necrotic regions were distribution in a serpiginous fashion, leaving "islands" of viable tissue
distributed throughout the tumor and near the tumor periphery. This growth pattern appeared
in the control mice as well as treated mice, and so it seems to be part of the normal growth
characteristics of this tumor cell line.
Since these tumor sections were dominated by necrotic tissue and therefore not amenable to
large-scale analysis entire tumor sections, small regions of vascularized viable tissue were
chosen for analysis. Many such regions were identified in each tumor section, resulting in tens
of vessels per dose schedule for subsequent analysis. This analysis (Figure 4.9) revealed a great
deal of heterogeneity in the distribution of antibody between tumor sections. All tumor
sections had antibody signal well above background in the perivascular region, but there were
no clear trends in the distribution among the daily, twice weekly, and weekly treatment groups.
On the average, all three treatment groups showed a perivascular antibody distribution with
detectable antibody penetrating to a distance of approximately 100 pm. However, the amount
of antibody detected was statistically indistinguishable across the three groups.
Mathematical modeling based upon a Krogh cylinder model of the tumor tissue has been used
previously to quantitatively probe the distribution of antibody around tumor blood vessels 0 20 .
When applied to HCT-116 tumors and known characteristics of EGFR endocytosis and
trafficking, the simulated distribution of daily, twice weekly, and weekly doses can be
generated as shown in Figure 4.11. All three dosing schedules are predicted to have similar
perivascular distributions, especially after 8 or more days of treatment. Experimentally, this is
exactly what was observed. The daily injection simulation suggests that tumor penetration is
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gradually enhanced over the first approximately one week of treatment, after which plasma
antibody concentrations have reached a consistent range as shown in Figure 4.3 and the
penetration profile has reached its maximum. In contrast, the more widely spaced doses are
separated by a time that is several times longer than the antibody serum half life, and so the
serum concentrations fall to near zero levels prior to each successive dose. As a consequence,
each dose exists essentially independent of the others and the penetration profile with these
dosing schedules is little changed with time.
It is important to note that this modeling does not take into account the pharmacodynamics of
the treatment. In this experiment, HCT-116 tumors were not consistently well controlled by
the HN-D/LC-A treatment, and so the experiment and model (which does not consider tumor
control or growth) can be compared with some degree of confidence. However, in a
therapeutic context in which effective targeting of tumor antigen can be expected to result in
some degree of cell killing, the model will need to be altered to take this into account. No
evidence of serial dosing strategies enhancing efficacy was seen with this model, but perhaps a
more efficacious drug would be more impactful and allow a better understanding of the
potential relationship between antibody penetration and antitumor efficacy.
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Figure 4.11. Numerical simulations of antibody distribution profiles based upon a Krogh cylinder
geometry and HCT-116 EGFR density and turnover rate. Parameters from the literature and measured
in the laboratory for antibody clearance, permeability and diffusivity, as well as tumor parameters such
as tumor cell density, antigens per cell, antigen turnover rate, and void fraction, were used to simulate
antibody distribution at varying times and for daily, twice weekly, and weekly antibody injections. In all
cases, a fixed 300 jig weekly dose was simulated and identical parameters other than antibody dosing
were used. PHarmacodynamic effects of treatment, e.g. receptor downregulation or tumor control, are
ignored in this simulation.
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5. ORTHOTOPIC AND ECTOPIC XENOGRAFT TUMORS
5.1 Introduction
Xenograft mouse models of cancer have been used for the study of cancer and to screen
potential cancer therapeutics in vivo for decades. Mice are inexpensive, can be bred rapidly,
and were among the first organisms to have their genome completely sequenced, advancing
the study of cancer genetics'. These models have contributed to the understanding of the
biology of cancer and to elucidating the efficacy and mechanism of action of many anticancer
agents. Because many different cancer cell lines representing cancers of many different types
and origins can be studied in xenograft models, they models have been perceived as very
flexible platforms.
The canonical host of xenograft tumors is the nude, or athymic, mouse. In 1972, it was shown
that nude mice, which lack a thymus and therefore lack mature T-cells and are unable to mount
an effective immune response against foreign tissue, can act as hosts for human tumor cells2.
Many preclinical drug efficacy studies have been carried out using the nude mouse model, most
often utilizing subcutaneous implantation of hundreds of thousands to millions of cancer cells
to generate a solid tumor. This model is in wide use because of the ease of inducing tumors
and the accessibility of the tumor which arises to observation and measurement. Virtually all
prospective therapeutics must prove efficacy in a mouse model of cancer before reaching
human clinical trials. However, the predictive power of subcutaneous xenograft models of
cancer is debatable3 .
A recent study by the National Cancer Institute attempted to examine the predictive power of
xenograft models by retrospective analysis of 39 oncology compounds with data on both
preclinical xenograft testing and phase 11 clinical trials. This study showed that fewer than half
of all compounds which showed substantial efficacy in mouse models showed statistically
significant clinical activity 4 . These data are complicated by the myriad variables inherent in
xenograft studies, e.g. site of implantation, size of tumor at treatment initiation, strain of
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mouse used, and route of administration. However, they do raise questions regarding the
predictive utility of subcutaneous xenograft models in the context of human disease.
One of the properties often lacking in subcutaneous xenograft models of cancer is interaction
with the host stromal tissue. Tumors are initiated by injection of hundreds of thousands to
millions of cells, which then begin to grow in the mouse. Once reaching a size of approximately
one millimeter in diameter, they must recruit murine vasculature in order to support their
continued growth5. Not only must murine vasculature be recruited to human tumor cells, but
the signaling pathways and molecules which are involved in angiogenesis are complex and
inconsistent between species6. In addition, it has recently become clear that stromal tissue in
the tumor microenvironment can play an important role in tumor signaling, angiogenesis, and
immune surveillance -1".
One of the fundamental differences between xenograft tumors and the clinical diseases which
they are intended to model is the placement in the body. Most xenograft tumors are implanted
subcutaneously, regardless of the type of tumor and the organ from which the tumor
originates. As a consequence, cancer cells which are derived from colorectal or lung cancer are
grown in a subcutaneous environment which little resembles the organ in which the primary
tumor formed.
In some cases, it is possible to establish tumors in an orthotopic fashion in the organ from
which the cancer cells are derived. These models are less common because they are generally
more difficult to establish. They may require surgery or image-guided implantation, and once
the tumors are established they are often not observable to the naked eye. In these cases,
tumor growth and development may be monitored by some form of in vivo imaging, but this is
more time consuming and often less precise than the simple caliper-based measurement of
subcutaneous xenografts". However, there is evidence to suggest that orthotopic and ectopic
tumors may have different properties with relevance to drug efficacy and drug development.
For example, although tumors in the clinic often metastasize, ectopic xenograft tumors virtually
never do, but some orthotopic models do metastasize in a pattern similar to the primary
tumors they seek to model12 1 s. Moreover, metastatic tumor cells injected into ectopic
89
locations in nude mice fail to metastasize, but injections into orthotopic locations often do
metastasize1. There is also evidence to suggest that the efficacy of drugs screened in
preclinical mouse models can vary depending upon whether the tumors are induced
orthotopically or ectopically 1. Presumably, these differences are due to the differing tumor
microenvironments and resulting biochemical and biophysical environments in which the
tumors grow.
In this work, we seek to examine two sets of tumors derived from human cancer cell lines and
induced orthotopically and ectopically in the same host mouse. We aim to determine whether
factors in the tumor microenvironment, such as vascular density and expression levels of
antigen, vary depending on tumor site. We also seek to evaluate whether the intratumoral
distribution of antibodies is affected by tumor location. This work has the potential to help in
choosing the appropriate mouse cancer model which captures the relevant features of the
disease while maximizing ease of use and accessibility of the model.
5.2 Materials and methods
Reagents
A low-picomolar humanized antibody to carcinoembryonic antigen (CEA), designated sm3e, has
previously been engineered and characterized'8 . In addition, murine IgG2a antibody TA99 has
been shown to target the melanosome protein gp75 which is highly expressed in melanoma".
This antibody was humanized and shown to retain binding to cell surface gp75. These
antibodies were secreted in transiently transfected HEK 293 cells (Invitrogen, Carlsbad, CA),
purified by protein A resin (Millipore, Billerica, MA) and buffer exchanged into PBS. Anti-CEA
monoclonal antibody M85151a was purchased from Fitzgerald (Acton, MA) and goat anti-rat
546 secondary antibody from Invitrogen. Antibody M85151a was labeled with an Alexa Fluor
647 Protein Labeling kit (Invitrogen) and has been previously determined to be noncompetitive
with sm3e 20. Human TA99 antibody was also labeled with an Alexa Fluor 647 protein labeling
kit.
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Animal model
Animal use and care was conducted in full compliance and under approval from the MIT
Committee on Animal Care. Two cell lines were utilized in this study. HT-CEA, a CEA-positive
human sarcoma cancer cell line, was used to induce subcutaneous xenograft formation in the
flank and intramuscular xenografts in the hind leg muscle of 6-8 week old Ncr nude mice
(Taconic, Hudson, NY) by injection of 1 x 106 cancer cells into each site. B16F10, a murine
metastatic melanoma cell line which highly expresses gp75, was used to induce subcutaneous
xenografts by injection of 1 x 10s cells into the flank and intramuscular xenografts by injection
of 2 x 105 cells into the hind leg muscle of NCr nude mice. Tumors were allowed to grow until
measuring 3-10 mm in diameter in each site, then either sm3e or TA99 was injected
retroorbitally into HT-CEA or B16F10 tumor bearing mice, respectively. Both antibodies were
administered at a dose of 20 pg, a dose chosen to be subsaturating of the tumor antigen. Mice
were sacrificed 24 hours after antibody administration, and tumors were immediately excised
and snap frozen in Optimal Cutting Temperature (OCT) medium (Sakura Finetek USA, Torrance,
CA) via isopentane over liquid nitrogen. Frozen blocks were stored at -80*C until sectioned by
the Koch Institute Histology Core Facility. Frozen blocks were sectioned approximately 1-2 mm
into the tumor tissue at a thickness of 8 im and stored at -80"C until stained and imaged.
Immunofluorescence protocol
Frozen slides were first air dried for approximately 30 minutes, then tissue samples circled with
a PAP pen (Invitrogen, Carlsbad, CA). Tissues were fixed for 10 minutes at room temperature in
formalin, then washed 3 times with PBS. Blocking was performed with 5% goat serum
(Invitrogen) in PBS for 1 hour at room temp. Primary antibody incubation was 5% goat serum in
PBS + 1:100 rat anti-mouse CD31 (BD Pharmingen, San Diego, CA) overnight at 4*C. Slides were
then washed three times with PBS, then incubated with PBS+0.1% Tween 20 (Sigma-Aldrich, St.
Louis, MO) + 1:200 goat anti-rat 546 (Invitrogen, Carlsbad, CA) + 1:100 goat anti-human Fc 488
+ 1:100 M85151a-647 (HT-CEA tumors) or 1:100 TA99-647 (B16F10 tumors) antibody for 1 hour
at room temperature. Slides were washed 4 times with PBS, then mounted in Vectashield +
DAPI medium (Vector Labs, Burlingame, CA).
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Fluorescence imaging
Slides were imaged using a DeltaVision Spectris microscope (Applied Precision, Issaquah, WA)
equipped with a motorized stage and running Softworx software (Applied Precision). Emission
and excitation filters were arranged to permit simultaneous 4-color imaging of DAPI, 488, 546,
and 647. The paneling feature of Softworx was used to capture the entire tumor section at a
resolution of 1.336 pm/pixel and to stitch together the fields into a single large mosaic image
for subsequent analysis.
Unbiased Image Analysis
Rather than introduce potential observer bias by manually selecting individual blood vessels for
analysis, images were analyzed as entire tumor sections for features including intervessel
distance, antibody penetration from blood vessels, and antigen distribution. The 546 nm (blood
vessel) plane was isolated, thresholded to include vessels only, and converted to a binary image
using ImageJ (NIH, Bethesda, MD). A Euclidean distance map was created from the vessel
binary, and this map was used as a mask to measure average intensity in the antibody (488)
plane as a function of distance from nearest blood vessel by an automated MATLAB (The
Mathworks, Natick, MA) computer program. Regions of the tumor revealed to be necrotic or
stromal tissue by examination of H&E staining or by absence of antigen were excluded from the
analysis.
5.3 Results
Xenograft tumors from both ectopic and orthotopic locations were immunofluorescently
stained for extravasated antibody and processed with an unbiased image analysis algorithm to
quantitate antibody intensity and localization relative to blood vessels. Results presenting the
data in a variety of ways are shown in Figure 5.1 for the HT-CEA cell line and Figure 5.2 for the
B16F1O cell line. Raw intensity data are shown for both sets of tumors, as well as data
normalized to the background signal present in antigen-negative regions of the tumor. This
normalization helps to elucidate the perivascular profile of the antibody signal since
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background signal can vary somewhat from section to section. Finally, for the HT-CEA tumor
sections, a noncompetitive anti-CEA antibody was used to visualize antigen distribution,
allowing the antibody signal to be normalized to antigen signal as a function of distance from
the nearest vessel. No such noncompetitive antibody was available for the B16F10 tumor
sections.
HT-CEA tumors highly express CEA at approximately 1 x 106 antigens per cell, and as predicted
by previous modeling analyses were poorly penetrated by the moderate dose of anti-CEA
antibody dosed in this model21. A perivascular distribution which is characteristic of many
monoclonal antibodies in solid tumors was observed, with the apparent penetration into the
tumor tissue measuring approximately 50-80 pm. No significant difference in antibody levels or
distribution profile was observed between the orthotopic and ectopic tumor models.
B16F10 tumors express the gp75 antigen on the cell surface. These tumors were also dosed
with antitumor antibody at a subsaturating level and showed a perivascular localization of the
antibody. The immunofluorescent signal from the bound antibody was detectable but
relatively weak, possibly due to signal attenuation attributable to the melanin pigment that is
highly expressed in this tumor. However, examination of the normalized antibody distribution
shows tissue penetration to a distance of 40-60 pm, and as in the HT-CEA tumor model no
significant difference in penetration distance or distribution profile is observed between the
orthotopic and ectopic tumor models.
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Figure 5.1. HT-CEA xenograft tumor antibody distribution around blood vessels. Top, raw antibody
intensity vs. distance from nearest blood vessel. Middle, antibody intensity normalized to background
vs distance from nearest blood vessel. Bottom, antibody intensity normalized to antigen signal at each
distance from nearest blood vessel. Red curves denote subcutaneous (ectopic) tumors and green curves
denote intramuscular (orthotopic) tumors.
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Figure 5.2. B16F10 xenograft tumor antibody distribution around blood vessels. Top, raw antibody
intensity vs. distance from nearest blood vessel. Bottom, antibody intensity normalized to background
signal vs. distance from nearest blood vessel. Red curves denote subcutaneous (orthotopic) tumors and
green curves represent intramuscular (ectopic) tumors.
A similar analysis was conducted on both sets of tumors to determine antigen expression levels
and intratumoral distribution (Figure 5.3). For the HT-CEA tumors, the noncompetitive anti-CEA
antibody allows the determination of antigen distribution throughout the tumor section. The
B16F10 tumors do not have a corresponding noncompetitive antibody, and so the antigen
intensity as measured by immunofluorescence is attenuated where extravasated antibody
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bound and occupies antigen. This is especially apparent near blood vessels, where the signal is
modestly reduced due to the relatively large amount of bound antibody in these regions.
Antigen analysis conducted on HT-CEA xenografts shows a highly variable antigen signal from
tumor-to-tumor. However, the variations in antigen levels do not appear to correlate with
tumor placement, as both ectopic and orthotopic tumors vary in their antigen expression levels.
Antigen intensity within individual tumor sections appears to be relatively homogeneous and
does not correlate strongly with distance from the nearest blood vessel. Several tumors are
exceptions to this and show a modest decrease in antigen signal with distance from nearest
blood vessel.
The B16F1O xenografts show a much more consistent degree of antigen expression (Figure 5.3).
Most of the tumors analyzed have very similar antigen expression levels. As in the HT-CEA
tumors, there is little change in antigen expression with distance from the nearest blood vessel.
It should be noted that any perivascular antigen level measurements may be altered by the
presence of antibody that extravasated and bound tumor antigen before the mouse was
euthanized, and so only data farther than the penetration distance of the antibody (40-60 pm)
from the nearest blood vessel is free from this potential source of error.
To examine the vascular density of the tumor tissue, histograms were generated for each tumor
type and tumor location of the fraction of tumor tissue present at each discrete distance (pixel)
from the nearest blood vessel. These plots are shown in Figure 5.4. All tumors show a similar
distribution of a large fraction of tumor tissue located quite close to blood vessels, with peak
fractional areas located within 50 pm of blood vessels. For HT-CEA tumors, the large majority
of the tumor tissue is located within 60 pm of the tumor tissue, indicating that these tumors are
highly vascularized. No difference in vascularity was observed in orthotopic vs. ectopic
placements of the HT-CEA cell line. The B16F1O tumors, however, showed a distribution shifted
toward greater distances from the tumor tissue. In these tumors the large majority of the
tumor tissue is located within 150-200 pm of the tumor tissue, indicating that they are much
less well vascularized. The B16F10 tumors also show a slight but insignificant difference in
vascularity by tumor location, with subcutaneous (orthotopic) tumors slightly less well
vascularized than intramuscular (ectopic) tumors.
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Figure 5.3. Antigen intensity and localization in xenograft tumors. Top, HT-CEA antigen distribution in
intramuscular tumors (orthotopic, red curves) and subcutaneous tumors (ectopic, green curves).
Bottom, B16F10 antigen (gp75) distribution in intramuscular tumors (ectopic, red curves) and
subcutaneous tumors (orthotopic, green curves). Note that the B16F1O anti-gp75 antibody used to
quantitate antigen levels is the same as the antibody dosed to the mice, leading to competition between
the antibodies and a decreased signal especially near the blood vessels where the antibody extravasates
and binds to a high degree.
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Figure 5.4. Tissue distribution around blood vessels histogram. The fraction of tumor tissue present at
each discrete distance from the nearest blood vessel is plotted. Top, HT-CEA and bottom, B16F10. Red
curves denote subcutaneous tumors and green curves intramuscular tumors.
98
5.4 Discussion
We present here a study of antibody distribution, antigen distribution, and vascularization of
mouse xenograft models of human tumors in orthotopic and ectopic locations. A previously
described method of immunofluorescence and unbiased quantitative image analysis allows the
determination of antibody as well as antigen intensity as a function of distance from blood
vessels at a resolution of approximately 1.25 microns. This analysis was applied to tumors
derived from two different cell lines, each implanted in both orthotopic and ectopic locations in
the same mouse. This creates a well-controlled model system for the determination of the
effects of tumor placement on antibody targeting.
As shown in Figures 5.1 and 5.2, all tumors and tumor locations showed antibody binding to
tumor antigen in a perivascular fashion. This distribution was anticipated from mathematical
modeling and predictions from the literature, and indicates that doses of antibodies to these
21tumors were below the level required to saturate the tumor antigen . Since the doses were
subsaturating, analysis of the perivascular distribution of antibody was possible. This analysis
did not show any dependence on tumor location in either the HT-CEA or B16F10 tumor cell
lines. Instead, all tumors showed a similar perivascular distribution profile. Each tumor type
was penetrated to a characteristic distance of ~50-80 pm for the HT-CEA tumors and ~40-60 pm
for the B16F1O tumors. No significant difference in penetration distance was seen in orthotopic
or ectopic tumor locations.
Quantitative analysis of antigen distribution and expression level was also carried out for all
tumors. The HT-CEA tumors were particularly amenable to this analysis because the availability
of a noncompetitive anti-CEA antibody allowed the entire tumor sections to be imaged and
quantitated without interference from the extravasated antibody dosed to the mice. These
tumors showed substantial tumor-to-tumor variability in antigen expression (Figure 5.3). The
B16F10 tumors showed considerably less variation in antigen expression. Across all tumor
types and locations, few tumors showed a strong variation in antigen expression versus
distance from the nearest blood vessel. This was expected, as the analysis was restricted to
areas of viable tumor tissue.
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Interestingly, analysis of tumor antigen expression in tumors matched to the mice in which they
grew shows patterns emerging (figure 5.5). The HT-CEA tumors show dramatic variation in
antigen expression within the same mouse, while B16F10 tumors do not show such variation.
In the HT-CEA tumors, most mice show higher antigen expression in the orthotopic location,
but the difference is not statistically significant and no such trend is seen in the B16F10 tumors.
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Figure 5.5. Comparison of antigen expression in orthotopic and ectopic tumors within in same mouse for
HT-CEA (top) and B16F10 (bottom) xenograft tumors. Antigen expression was quantitated as the fold
over background for the average of the antigen intensity from 40-60 ptm from the nearest blood vessel.
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The vascularization of the two different tumors is dramatically different (Figure 5.4). The HT-
CEA tumors are very vascularized and the large majority of tumor tissue is located within
approximately 50 pm of the blood vessels. Virtually no tissue is farther than 100 pm from the
vessels. In contrast, the B16F10 tumors are much less vascularized and viable tissue exists out
to approximately 200 pm, which agrees well with the diffusion limit of oxygen . Again, though,
little difference in vascularity is seen within a tumor type between orthotopic and ectopic
tumor locations.
These results seem to suggest that, at least for these tumor models, tumor location does not
play a significant role in the microdistribution of antibodies in tumor tissue. One potential
explanation for this is that for xenograft tumors, the majority of the tumor microenvironment is
made up of tumor cells and little stromal tissue is present in the tumor. As a result, the
transport of macromolecules through the tumor interstitium is consistent across tumor
locations. It has previously been shown that interstitial fluid pressure (IFP) can be higher in
orthotopic tumors than ectopic tumors23. It could be argued that this would be expected to
impede the transport of antibodies into orthotopic tumors. However, it has also been shown
that tumors have elevated IFP in general and that this serves to reduce convective transvascular
transport to a level that is negligible relative to diffusive transport 24-26. In this case, elevated IFP
would have little effect on antibody transport because it is primarily diffusive in nature.
Another potential cause of the similarity in properties between orthotopic and ectopic tumors
is the nature of xenografts. The tumor tissue appears histologically homogeneous as a layer of
tumor cells with very little secondary structure. As such, inside the tumor there is little contact
with the host tissue surrounding the tumor. Only at the edges of the tumor are interactions
apparent as depicted in Figure 5.6. As shown, there are regions in the HT-CEA intramuscular
(orthotopic) tumor site which clearly show invasion of the tumor tissue into the surrounding
muscle fibers. However, these regions make up only a small fraction of the tumor tissue in this
xenograft model. We believe that models which capture this invasive nature and the physical
interaction of host tissue and tumor tissue are important for future investigations into the role
of the tumor environment on the transport and penetration of antibodies into the tumor tissue.
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Figure 5.6. Immunofluorescent image of the antigen (CEA) in a HT-CEA xenograft tumor placed in the
intramuscular (orthotopic) location. The dim tissue in the upper left of the image is the muscle, and the
"holes" in the tissue near the boundary of the tumor and the muscle are muscle fibers. Tumor tissue in
this region is actively invading into the muscle.
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6. DEVELOPMENT OF AN AUTOCHTHONOUS CEA-EXPRESSING MOUSE
MODEL
6.1 Introduction
Mice have been used as model organisms for in vivo laboratory research for over one hundred
years. Mice are appealing organisms for the study of cancer for many reasons, and the
laboratory mouse has become the standard preclinical in vivo model system that is used in drug
development for cancer. They require little space or food, reproduce relatively rapidly, and are
easy to handle. For decades, they have been used to study tumorigenesis, the disposition and
trafficking of candidate drugs, and often the in vivo efficacy of candidate drugs as a prelude to
first-in-human studies.
Early mouse models of cancer used direct administration of carcinogenic compounds to induce
tumor formation in mice'. More recently, advancements in mouse models have led to the
development of over 450 different strains of mice which have been bred for specific phenotypic
or genotypic characteristics2. These strains are often inbred for tens of generations, creating
lines of mice which are genetically identical to one another. This has allowed researchers to
use the same mouse models regardless of geographical location and has aided reproducibility
and translation of research. Some of these inbred models were bred for the study of cancer
and were predisposed to certain types of cancer 3. Despite these advances in mouse models,
the study of cancer in these models continued to be difficult as a consequence of the
unpredictable development of tumors in these mice.
A major breakthrough in mouse cancer models was achieved with the advent of
immunocompromised mouse models. The first immunocompromised mice to be widely used in
cancer studies were athymic, or nude, mice4. Sine these mice lack a thymus, they fail to
develop mature T cells and are unable to mount an effective response against many immune
stimuli. Other immunocompromised mouse strains have since been developed, incuding the
widely used severe combined immunodeficient (SCID), which lacks functional T cells and B cells
due to a defect in V(D)J recombination5 . A further step has recently been taken by creating
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SCID mice lacking the interleukin-2 receptor, rendering these mice without function B cells, T
cells, or natural killer (NK) cells6. These immunocompromised mice all are able to accept
xenografts of human cancer cells, which in many cases develop into solid tumors at the site of
injection into the mouse. Xenografted mice allow many different types of cancer to be studied
using in vivo hosts which are genetically identical to one another. Today, nearly all cancer
therapeutics are tested first in xenografted mice before being tested in humans.
Despite the utility of xenograft mouse models, there remain many difficulties in translating
results seen in the context of a mouse xenograft to clinical studies. A recent metastudy of
approximately 40 anticancer drugs which were tested in xenograft mice as well as in human
clinical trials suggested that less than half of all drugs efficacious in xenograft models were also
efficacious in human trials7. Xenografted mice are most often used in subcutaneous tumor
models in which tumor cells are injected under the skin of the mice. Advantages of this model
include a high penetrance rate, accessibility for both tumor cell injection and subsequent
measurement of the tumor size, and relatively low technical barrier. However, these models
can be crude approximations of clinical tumors (Figure 6.1). They are not clonal in origin,
instead originating from thousands to millions of cultured human cell lines, often passaged over
tens or hundreds of generations in plastic dishes before being injected. It has been shown that
most primary cells are not well propagated in vitro, and further that the cells which are
successfully propagated and immortalized in tissue culture often lose many of the
characteristics of the original host and tumor8'9. Genetically, they are often highly abnormal,
and have been shown to change their genetic makeup over time in culture0 '. Finally, these
tumor cells are growing in an environment that is in many ways a poor reproduction of a tumor
environment. They grow under the skin of a mouse without a properly functioning immune
system, and must interact with mouse growth factors, recruit murine vasculature, and in
general communicate intercellularly with a murine host. Not surprisingly, xenograft models of
cancer have a mixed track record in the context of preclinical drug development.
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Figure 6.1. At left, an example of a hematoxylin and eosin (H&E) stained xenograft tumor section. Note
the homogeneity of the tissue and the lack of secondary structure. At right, an example of a colorectat
cancer xenograft. Notice the heterogeneity of the tissue and the distinct presence of secondary
structures. Also note that a large fraction of this section is composed on stromal cells, which are often
largely absent in xenograft tumors.
There have been many notable failures of drugs which were highly efficacious in mice, but have
failed miserably in human trials. The attrition rate of drugs which reach clinical trials is quite
high, and various estimates place the attrition rate at 60-95% . These drugs were all successful
in mouse studies, yet faltered in human studies, raising questions about the ability of xenograft
models to capture the fundamental features of the human disease. The high failure rate of
clinical compounds which were successful in mouse studies also raises the question of whether
promising therapeutics for humans may be overlooked because of poor efficacy in mice. One
possible cause of the discrepancy between xenograft mouse models and human trials is the
deficient immune system which exists in these mouse models.
In the past several decades, a new generation of mouse models of cancer has been developed,
and these models are often fully immunocompetent. These models are genetically engineered
to knock out or knock in certain genes which are relevant to the study being conducted12 . For
example, knocking out tumor suppressor genes and/or knocking in oncogenes has been shown
to lead to tumor formation. Other genes can be tweaked to constitutively activate certain
pathways, or to develop mice which lack a certain specific characteristic, for example a
particular immune function. Still others can aid in research by activating fluorescence or
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inducible markers in response to external stimuli'3 14 . There has been an explosion in the
development of these models in recent years, and they have greatly facilitated the study of the
biology and pathology of cancer. Unfortunately, genetically engineered mouse models are
often expensive and slow to develop, and this has hindered their development and use in the
context of preclinical efficacy evaluation and drug development15.
In this work, we seek to build upon a previously described genetically engineered mouse model
to develop a model which is engineered to express a neoantigen that can be targeted by an
antibody',"7 . This model of cancer is engineered upon the most common strain of laboratory
mouse in the world, the C57BL/6 mouse. The Jacks laboratory has made two modifications to
the mouse genome, both of which are activatable upon the administration of the enzyme Cre
recombinase. This enzyme can be delivered specifically to certain organs of the mouse by
administration of a lentivirus engineered to insert the gene for Cre recombinase into the mouse
genome. Upon exposure to Cre recombinase, two events occur. First, the oncogene K-ras with
a common mutation (G12D) to confer constitutive activity is activated through the excision of a
stop codon preceding it. Second, the tumor suppressor gene p53 is excised from the genome.
The mice which possess this genotype are abbreviated KP mice. Constitutive activation of K-ras
and loss of p53 function mutations occur commonly in cancer, particularly in the most frequent
and most deadly cancer that occurs in humans, lung cancer 1'1 . The effect of these two
mutations is to transform single cells possess a tumorigenic genotype. Over a period of weeks
and months, tumors form in the affected organ from a clonal origin, gradually becoming
increasingly neoplastic as the tumors develop. The tumors which form are histologically very
similar to human tumors and mimic the progression of human tumors. Eventually, all affected
mice die of their tumor burden, and to date no therapeutic strategy has been effective in curing
a mouse affected by these tumors.
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Figure 6.2. H&E staining of lung sections from KP mice at varying time points after viral infection.
Tumors form and over time become increasingly aggressive, eventually invading into stromal tissue and
even metastasizing. This pathological process is histologically similar to human non-small cell lung
cancer. Figure courtesy of Leah Schmidt and adapted from 16
The KP mouse model has been used in several studies of cancer biology and
tumorigenesis17,18,20-2 . It has seen limited use in studies of preclinical anticancer drugs, and KP
mice have yet to be cured by any experimental treatment. The tumors which arise lack any
known antigen, and so targeted therapies have not been tested on this model because no
molecular target is known. We seek to build upon this model by engineering a lentivirus that
will induce the expression of Cre recombinase to initiate the tumor, and simultaneously
introduce a neoantigen, carcinoembryonic antigen (CEA). The CEA antigen is commonly used in
preclinical cancer models and has well-understood biology and structure 2-33. It has also been
used in numerous preclinical studies, and has been used clinically in settings ranging from use
as a biomarker for cancer progression to use as a target antigen for therapeutics in clinical
trials26,34-37 . We seek to induce CEA-expressing autochthonous tumors in immunocompetent
mice to create a next-generation genetically engineered mouse model for use in studying
cancer biology and the efficacy of potential targeted therapeutics.
6.2 Materials and methods
Development of lentiviral vectors
Lentiviral transfer vector NLSCre-zsGreen was obtained as a gift from the Jacks laboratory
(Cambridge, MA). Using the QuikChange method, full length CEA (2109 bp) and truncated CEA
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containing only the sm3e antibody epitope and the GPI linker (~800 bp) were inserted into the
transfer vector, replacing the zsGreen sequence38 . These constructs were termed lenti-CEA and
lenti-CEAfrac, respectively. Two truncated CEA variants were created-the first consisting of
the two binding domains making up the sm3e epitope, in addition to the GPI linker, and the
second consisting of the same elements joined by a (Gly)4(Ser) linker to separate the binding
site from the cell surface (lenti-CEAfrac and lenti-CEAfrac G4S, respectively). In addition, one
other construct was created by excising the woodchuck response element (WRE) from the full-
length CEA transfer vector in an attempt to reduce the overall size of the plasmid for enhance
virus production. The construct was termed lenti-CEA AWRE.
LSL G12D/+. 53 /f
K-ras -G/p53fl mouse preparation and lentivirus injection process
K-rasLSL-Gl 2 D/+;p53fI/fI (hereafter referred to as KP) mice were obtained as a gift from the Jacks
laboratory at M.I.T.(Cambridge, MA). The mice were bred to one another and neonates
genotyped to determine the mice possessing the KP genotype. Mice of a similar age with the
desired genotype were used in viral administration studies.
Viral administration was conducted as per the protocol described previously by literature
published from the Jacks laboratory 6 . Briefly, mice were anesthetized by i.p. injection of
Avertin (0.4 mg/g). The anesthetized mice were then placed upon an intratracheal delivery
platform (Lab Inventions, Newton, MA) and a Fiber-Lite Illuminator (Dolan-Jenner, Boxborough,
MA) was positioned against the chest of the mouse to illuminate the chest cavity. Taking care
not to scratch or puncture the mouse, a 22 gauge Exel Safelet IV catheter (Fisher Scientific,
Pittsburgh, PA) was inserted into the trachea of the mouse. Once inserted, a 50 p1 of solution
of 25,000 infectious viral particles in serum-free Dulbecco's Modified Eagle Medium (Life
Sciences, Grand Island, NY) was administered through the catheter. The catheter was then
removed and the mouse allowed to recover under a heat lamp until conscious. Infected mice
were returned to their cages and monitored at least twice weekly during the course of the
experiment.
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Lentivirus production process
Lentivirus was produced in human embryonic kidney 293FT (HEK293FT cells) acquired from Life
Sciences (Grand Island, NY). HEK293FT cells were cultured in supplemented Dulbecco's
Modified Eagle Medium (DMEM) as per the manufacturer's instructions. Cells were plated onto
large diameter 15 cm cell culture plates for virus production and grown to approximately 50%
confluency on the day of transfection. On the day of transfection, the cells were transfected
using polyethyleneimine (PEI), and transfer vector, packaging vector A8.9, envelope vector VSV-
G, and pAdvantage translation enhancement vector (all gifts from the Chen or Jacks laboraties
at M.I.T.) in a 2:1:1:1 ratio of 10 pg transfer vector and 5 pg of all other vectors. Briefly, 60 pl of
1 mg/mL 25,000 MW PEI (Polysciences, Warrington, PA) was added to 540 p1 OptiPro (Life
Sciences). Then, DNA in the quantities and ratios above were added to a second tube of 600 pl
OptiPro media. The tubes were incubated in a biosafety cabinet for 5-10 minutes at room
temperature, then the contents of the DNA tube were added to the PEI tube. The combined
mixture was incubated 10 minutes at room temperature, then added dropwise to the 15 cm
plate of HEK293FT cells. Cells were incubated 6-12 hours with the transfection reagents, then
the media was changed and replaced with supplemented media free of DNA and transfection
reagents. At 48 hours following transfection, the supernatant (20 mL of media) was collected,
filtered through a 0.45 pm syringe filter, and refrigerated. Fresh media was added to the plate,
and at 72 hours this media was also collected, 0.45 pm filtered, and added to the first
supernatant. The pooled supernatant contains viral particles, and was spun in an
ultracentrifuge at 25,000 rpm for 2 hours at 4*C. The supernatant was aspirated, and the viral
pellet resuspended in 400 pl PBS and incubated overnight at 40C. The virus was next titered for
activity on 3TZ reporter cells.
Titration to determine lentivirus activity
To determine the activity of the viral supernatant, the 3TZ reporter cell line was used for
titrations of the virus. This cell line contains a lox-conditional LacZ/$-Gal gene, and if infected
by a Cre recombinase-expressing virus undergoes activation of the LacZ gene. The day before
the titration, the 3TZ cells (Jacks laboratory, M.I.T., Cambridge, MA) were plated onto 6-well
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plates at 1x105 cells/well. The next day, dilutions of virus were added to the wells of the 6-well
plate in duplicate at 1:100, 1:1000, and 1:10000 ratios. Virus was incubated 24 hours, then the
media replaced by fresh media. At 48 hours following infection, the media was aspirated and
the cells washed with PBS. The cells were then fixed for 10 min with 3.6% formaldehyde (Sigma
Aldrich, St. Louis, MO) in PBS. The wells were then washed 3 times with PBS, and X-Gal solution
was added to cells and incubated overnight in a 370C incubator. X-Gal solution consists of 10
mL PBS, 250 pl 20x K3Fe(CN)6/K 4Fe(CN) 6, 400 pl X-Gal stock solution, and 20 Pl 1M MgCl 2. The
X-gal stock solution is composed of 25 mg/ml X-gal in N,N-Demethylformamide, stored at -20*C.
The 20x K3Fe(CN) 6/K4Fe(CN)6 is composed of 3.292g K3Fe(CN) 6+4.224g K4Fe(CN) 6+100ml PBS,
stored at 40C in a foil-wrapped container protected from light
Micro computed tomography for in vivo imaging of lung tumors
Mice were imaged on an eXplore CT120 whole mouse microCT (GE Healthcare, Waukesha, WI)
every two weeks beginning at 10 weeks post infection. The imaging protocol used was "soft
tissue fast scan", a protocol balancing image resolution and radiation exposure. Imaging
parameters were as follows: 220 views, 0.8770 increment angle, 70.0 kV X-ray tube, 50.0 mA X-
ray tube current, 2x2 binning, 32 ms exposure time, 130 gain, and 20 offset. Once images were
acquired, reconstruction was performed on the region containing the lungs and images saved
for analysis with lmageJ software (National Institutes of Health, Bethesda, MD).
Treatment with interleukin 2-Fc + anti-CEA antibody
Beginning at 14 weeks post-infection, one mouse in the lenti-X group and one mouse in the
lenti-CEAfrac group was treated with an experimental immunocytokine therapy. This therapy
consisted of 25 pg of interleukin-2 fused to a murine IgG2a Fc domain coadministered with 100
pg of high affinity sm3e anti-CEA antibody with a murine IgG2a backbone. Both constructs
were administered in approximately 50 pl of PBS weekly into the mouse via retroorbital
injection. When possible, injections were conducted at the same time, but spatially separated
by injecting each construct into a different eye of the mouse. Weekly injections continued for
14 weeks or until death of the mouse.
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Detection of anti-CEA antibodies in serum of KP mice
Biotin binder Dynabeads from Life Sciences (Grand Island, NY) were prepared as per the
manufacturer's instructions. Human CEA purified from colon carcinoma was acquired from
Fitzgerald Industries (Acton, MA) and biotinylated using Pierce EZ-Link Sulfo-NHS-Biotin reagent
(Thermo Fisher Scientific Inc, Rockford, IL) according to the manufacturer's protocol.
Biotinylated CEA was thoroughly desalted by passage twice through 7 kDA MWCO Zeba
desalting columns (Thermo Fisher Scientific). Then, 2.5 pg of biotinylated CEA was incubated
with 2x10 7 biotin-binder Dynabeads for 1 hour at room temperature on a rotator, then washed
twice in PBS and resuspended at a density of 200,000 beads/pl.
To detect anti-CEA antibodies, 200,000 CEA coated beads were incubated with serum dilutions
(1:10 or higher) or controls for one hour or more at room temperature on a rotator. Beads
were then washed twice with PBS+0.1% albumin (PBSA) and resuspended in 100 p1 PBSA. Anti-
mouse secondary conjugated to Alexa Fluor 488 (Life Sciences) was added at a 1:200 dilution
and incubated 30 minutes at 40C on a rotator. Beads were washed twice with PBSA, and finally
resuspended in 100 pl PBSA and kept on ice until running on an Accuri C6 cytometer (BD
Biosciences, San Jose, CA).
Histology and immunodetection of CEA
Mice were sacrificed by CO2 asphyxiation. Immediately following euthanasia, four of the five
lobes of the lungs, draining lymph nodes, spleen, kidneys, liver, and heart were removed, fixed
12-24 hours in 3.6% formaldehyde in PBS, and stored in 70% ethanol until being paraffin
embedded by the Koch Institute Histology Core Facility. The fifth lobe of the lungs was
removed, embedded in Tissue-Tek optimal cutting temperature (OCT) media (Sakura Finetek,
Torrance, USA), and flash frozen in isopentane over liquid nitrogen. Frozen tissue was stored at
-80*C until being sectioned by the Koch Institute Histology Core Facility at 6 pm thickness and
kept at -800C until use. Paraffin-embedded sections were sectioned by the facility at 5 pm
thickness and kept at room temperature until use. For most tissues, one slide was hematoxylin
and eosin stained for analysis of tissue morphology and pathology.
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For immunohistochemical detection of CEA, lung sections were dewaxed, rehydrated, and then
fixed for 10 minutes in 3.6% formaldehyde in PBS. Sections were washed with water, then
boiled for 10 minutes in 10 mM sodium citrate, pH 6.0, for antigen retrieval. Slides were
allowed to cool at room temperature for 20 minutes, then washed three times in water. Slides
were blocked with 1% hydrogen peroxide in water for remove endogenous peroxide activity. A
MaxTag Histo IHC kit (Rockland Immunochemicals, Gilbertsville, PA) was used according to the
manufacturer's protocol for IHC staining using the human anti-CEA antibody sm3e as the
primary antibody at a 1:2000 dilution. Slides were imaged using a Zeiss upright microscope.
An immunofluorescence protocol was applied to frozen lung samples to detect the presence of
human antibody through human Fc and the detection of CEA on the cell surface. Anti-CEA
monoclonal antibody M85151a was purchased from Fitzgerald (Acton, MA) and goat anti-rat
546 secondary antibody from Life Sciences. Antibody M85151a was labeled with an Alexa Fluor
647 Protein Labeling kit and has been previously determined to be noncompetitive with
sm3e 33 . Tissues were fixed for 15 minutes at room temperature in formalin, then washed 3
times with PBS. Blocking was performed with 5% goat serum (Invitrogen) in PBS for 1 hour at
room temp. Primary antibody incubation was 5% goat serum in PBS + 1:100 rat anti-mouse
CD31 (BD Pharmingen, San Diego, CA) overnight at 40C. Slides were then washed three times
with PBS, then incubated with PBS+0.1% Tween 20 (Sigma-Aldrich, St. Louis, MO) + 1:200 goat
anti-rat 546 (Invitrogen, Carlsbad, CA) + 1:100 M85151a-647 anti-CEA antibody (Fitzgerald,
Acton, MA) for 1 hour at room temperature. Slides were washed 4 times with PBS, then
mounted in Vectashield + DAPI medium (Vector Labs, Burlingame, CA). Slides were allowed to
set a minimum of 12 hours and imaged on a DeltaVision fluorescence microscope.
6.3 Results
Production of CEA-inducing lentivirus
Lentivirus production is a strong function of the size of the transfer vector 39, and CEA is a large
neoantigen to be inserted into the transfer vector at approximately 2100 bases. In comparison,
other neoantigens used in the KP mouse model include luciferase20,21 (~1700 bp) and green
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fluorescent protein (personal communication with Leah Schmidt, Jacks lab) (~800 bp). The
smallest KP transfer vector, contained only Cre recombinase and no neoantigen and termed
lenti-X, has a high viral titer, but the addition of transgenes drops the viral titer substantially.
The first step in the development of a robust CEA-expressing KP mouse model was to
determine whether virus encoding both Cre and CEA (lenti-CEA virus) can be produced in
sufficiently high titers. To examine this, lenti-X, lenti-GFP (expressing Cre recombinase and
GFP) and lenti-CEA viruses were produced as described earlier and titrated on 3TZ reporter
cells. The results are shown in Figure 6.3 below.
Lenti-X (8.8 kb)
Lenti-GFP (9.5 kb)
Lenti-CEA (10.9
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Lenti-CEA AWRE
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Figure 6.3. At top, schematic illustrations of the various lentiviral transfer vectors used. Lenti-X is the
smallest construct and contains only Cre recombinase, while all the others contain Cre in addition to a
transgene. Lenti-CEA AWRE contains full length CEA but excises the woodchuck response element
(WRE) to decrease the total size of the insert. At bottom, titaration results with each of the four viral
vectors on 3TZ reported cells. Data are shown as number of infected 3TZ cells per plate of virus
produced. Dotted line represents the number of infections required to infect a single mouse.
For the smaller constructs, such as the minimalist lenti-X and the relatively small lenti-GFP,
transduction efficiency is good and titration results indicate that several plates of virus
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production would allow the production of enough virus to infect multiple mice at the
recommended dose of 25000 infectious particles per mouse.. However, the lenti-CEA construct
is over 2 kb larger than lenti-X, and the result is production of more than three orders of
magnitude less infectious virus. Removal of the WRE element had little effect on the viral titer,
perhaps because the WRE has been shown to improve viral translation, and so perhaps the
decreased vector size was offset by reduced translational efficiency44.
To address this issue, additional transfer vectors were created of a reduced size, but containing
the sm3e epitope of CEA. The CEA antigen is a long, rod-like protein consisting of a
glycophosphatidylinositol (GPI) linker and seven immunoglobulin domains26 ,29 ,41. The binding
site for sm3e has been mapped to a location between the first and second immunoglobulin
domains farthest from the GPI linker,26 42 . Based on this data, a truncated version of CEA was
created consisting of the two immunoglobulin domains compromising the antibody binding
domain conjugated to the GPI linker domain. An additional vector was created with the
addition of 2 (Gly)4(Ser) spacers between the immunoglobulin domains and the GPI linker to
provide a flexible linker to separate the binding domain from the cell surface and reduce the
potential for steric hindrance. Both these truncated versions of CEA measure approximately
800 base pairs in length, reducing the size of the transfer vector approximately 1300 base pairs
relative to the full length CEA and bringing them into the same size range as lenti-GFP.
Complete sequences for these vectors are provided in Appendix B. Once created, these vectors
were transfected into HEK293FT cells and virus produced and the transfected HEK cells checked
for binding binding against Alexa Fluor 488 labeled sm3e, then run on an Accuri C6 flow
cytometer to determine whether the fractional CEA retained the sm3e epitope while on the cell
surface. Results are summarized in Figure 6.4 below.
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Figure 6.4. Validation of anti-CEA antibody binding to fractional CEA constructs. A, cartoon of CEA
structure and sm3e antibody binding pocket from 42. B, 3TZ reporter cell titration results demonstrating
that fractional CEA is produced by HEK293FT cells at levels sufficient for infecting mice (black dotted
line, amount of virus need per mouse). C, flow cytometric analysis of HEK293FT cells for determination
of antibody binding to fractional CEA. Transfected HEK cells were incubated with Alexa 488-labedl sm3e
and run on flow. Left panel, black is negative control (untransfected HEK cells), red is full length CEA,
blue is fractional CEA, and yellow is fractional CEA with G4S linker. Right panel, direct comparison of the
three CEA constructs. Note that there is no discernible difference in the antibody binding between the
three. In all cases, transfection efficiency was approximately 20%.
The truncated CEA transfer vector results in the production of more than 10 fold less virus than
lenti-X, but several orders of magnitude more than lenti-CEA. More importantly, the titer of the
truncated CEA is in the range such that a single plate of transfected HEK cells results in enough
virus to infect one or more mice, making the production of virus by this method feasible even
for relatively large cohorts of mice. The virus produced was used to infect a cohort of five KP
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mice, three of which received 25,000 infectious particles of lenti-CEAfrac G4S and two of which
received 25,000 infectious particles of control virus lenti-X.
Evaluation of lung tumor development in vivo
The tumors which are induced by viral infection are expected to be localized to the site of viral
administration, in this case the lungs. To track lung tumor development and tumor burden,
micro computed tomography (pCT) was utilized beginning 10 weeks post-infection. This
technique has proven effective in imaging KP mouse tumors and tracking tumor burden
longitudinally22 . By this method, tumors of a size of approximately 1 mm in diameter can be
detected (Figure 6.5).
Figure 6.5. Representative pCT images of KP mouse lungs. At left, a lung with no detectable tumors.
The large white object marked with an asterisk (*) is the heart. Center, a lung with several detectable
tumors, marked with white arrows. Right, the lungs of a mouse with advanced lung cancer and many
tumor nodules. This mouse was euthanized due to morbidity from tumor burden approximately one
week following this image.
By tracking the progression of the tumors in the five mice infected with lentivirus, it was
possible to track the development of tumors and the tumor burden over time. The first
evidence of tumors detectable by pCT occurred at approximately 12 weeks post-infection.
Treatment with Fc-1L2 + murine sm3e began in two mice (one lenti-X and one lenti-CEA) during
week 11. The three untreated mice all exhibited evidence of small (1 mm diameter) tumor
nodules evident in pCT scans by week 16. However, the treated mice failed to show evidence
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of tumors until much later-no tumors were evident at the time of the death of the treated
lenti-X mouse (week 19), and only very small tumors were apparent at week 26 in the treated
lenti-CEA mouse. Fc-IL2 treatment of this mouse continued for 14 consecutive weeks beginning
with week 11 before being discontinued.
Tumor size was qualitatively assessed through the biweekly pCT scans. While only one control
mouse was used in this study, this mouse developed tumors visible to PCT scans first and
continued to develop a large tumor burden until being euthanized due to tumor burden at
week 24. The two lenti-CEA mice that did not receive Fc-IL2 + murine sm3e treatment both
developed visible tumor nodules just a few weeks after the control mouse, but the rate of
tumor growth was considerably slower and no mice died until one was euthanized to test for
the presence of CEA at week 25. The remaining lenti-CEA mouse exhibited continued tumor
growth by pCT through 32 weeks, at which point the mouse possessed a moderate tumor
burden.
The CEA protein is not found endogenously in mice, and so its introduction into an
immunocompetent mouse model such as the KP model could cause an immune response
against the antigen as has been observed with several canonical immunogens in the past2,2
In this case, the CEA protein might fail to be expressed through immunoediting, allowing the
tumor to grow out without expressing the desired antigen. To determine whether CEA was
expressed in tumors generated in lenti-CEA mice, we first checked whether an immune
response was raised against CEA by testing the serum of mice infected with lenti-CEA for the
presence of circulating anti-CEA antibodies. Beads coated with full length CEA were incubated
in the serum of lenti-CEA mice and controls, and the results are summarized in Figure 6.6. For
all lenti-CEA mice, anti-CEA antibodies were detected at levels well above background, while
anti-CEA antibodies were absent in all lenti-X mice and uninfected control mice.
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Sample Name
* A06 KPB ser + 10 nM msm3e.fcs
A05 KPB ser + 1 nM msm3e.fcs
A03 Naked beads in ctri serum.fcs
A04 Beads in serum+secondary.fcs
2 4 610 10 10
FL1-A
2 4 6
10 10 10
FLI-A
Sample Name
Al0 KP 84 100x dil.fcs
* A09 KP 84 50x dil.fos
A08 KP 84 25x dilfcs
A07 KP84 10x dil.fcs
A04 Beads in serum+secondary.fcs
C
0
0
2 4 610 10 10
FL1-A
Sample Name
* B10 KP47 100x dil.fcs
B 809 KP47 50x difCs
B 808 KP47 25x diIfcs
I B07 KP47 10x dil.fcs
M A04 Beads in serum+secondary.fcs
Figure 6.6. Flow cytometric testing for the presence of anti-CEA antibodies in the serum of control and
lenti-CEAfrac G4S mice. The presence of antibodies bound to CEA-coated beads was determined using a
488-labeled anti-mouse antibody. A, control mouse showing no antibodies present in the serum and a
2-3 log shift upon spiking anti-CEA antibody (m-sm3e). B and C, two different lenti-CEAfrac G4S mice
showing the presence of antibodies even at 1:100 dilutions of the serum.
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Following the death due to tumor burden of the lenti-X control mouse, one of the lenti-CEA
mice with clear tumor nodules measuring 1-2 mm diameter by pCT was euthanized and the
lungs excised for histological analysis. The lenti-X control mouse was subjected to similar
histological analysis following euthanasia. These tumor sections were analyzed with H&E
staining to examine and confirm tumor pathological characteristics (Figure 6.7). Examination of
the lenti-X and lenti-CEA tumors showed that the tumors had pathological characteristics
similar to human non-small cell lung cancers as has previously been observed for KP mice.
The lenti-CEA tumors showed a much greater degree of lymphocyte infiltration into the tumor,
particularly at the tumor periphery, than the lenti-X tumors. By pathological grade, the lenti-X
lung tumors were mostly grades 2 and 3, with several tumors potentially grade 4 and showing
evidence of invasion into surrounding tissue and potentially metastasizing, although no
metastases were observed in the mouse. The lenti-CEA tumors were lower grade, grades 1 and
2 with at least one grade 3 tumor, consistent with the decreased tumor burden at the time of
the mouse's euthanasia.
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Figure 6.7. H&E stained lung sections from lenti-X (top panels) and lenti-CEAfrac G4S (bottom panels).
Several tumors of varying size and grade are shown. Histology is similar to that seen in previous KP
tumors and mimics the histology of human non small cell lung cancer. Note the large numbers of tumor
infiltrating lymphocytes which are seen in the lenti-CEAfrac G4S tumors (bottom panels) but at a much
lower frequency in the lenti-X controls.
Sections of the lenti-X and lenti-CEA lungs, along with sections of xenograft tumors known to
express CEA, were subjected to immunohistochemistry in an attempt to detect the presence of
cell surface antigen recognized by the sm3e antibody (Figure 6.8). CEA expression was
confirmed in the LS174T and HT-CEA tumor sections, which are known to express
approximately 4x10s and 1x106 CEA molecules/cell in vitro33,44. However, no evidence of
cellular CEA expression was observed on either lenti-X control tissue or lenti-CEA tissue.
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Figure 6.8. Immunohistochemistry to detect the presence of CEA on tissue sections. Images are shown
at 10x magnification (top row) and 40x magnification (bottom row). Two positive control tumors, HT-
CEA (106 CEA/cell) and LS174T (4x105 CEA/cell), were stained for comparison with tumor-bearing lenti-
CEAfrac G4S tissues. The presence of cell -surface CEA is apparent in the positive control tumors, but
results are ambiguous in the lenti-CEAfrac G4S tissue.
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6.4 Discussion
Thus far in the development of an authochthonous CEA-expressing immunocompentent mouse
model, only one control mouse and one putative CEA-expressing mouse has been histologically
examined. The histological data are inconclusive regarding the presence of CEA in this model
(Figure 6.8). Although immunohistochemistry did now demonstrate the presence of the
antigen, it is possible that expression is present but low and under the detection limit for this
IHC protocol.
However, the presence of anti-CEA antibodies in the serum of mice infected with virus
containing CEA (Figure 6.6) is highly suggestive of successful induction of CEA expression at
some point during the experiment. Antibodies are present at relatively high titers, as indicated
by the relative lack of decreased signal even at high (1:100) dilution of serum. At this point, the
possibility that the antibodies might be raised in response to residual CEA protein in the viral
supernatant cannot be ruled out. Although the supernatant is centrifuged at 25,000 rpm for 2
hours to pellet virus, it is feasible that small amounts of CEA persist and that the virus acts as a
powerful adjuvant to drive an anti-CEA immune response to the dosed CEA. However, the fact
that the lung is generally an immunosuppressive environment would argue against such a
strong response. In addition, the histological differences between lenti-CEAfrac and lenti-X
tumors, in particular the dramatically enhanced lymphocyte infiltration into the putative
antigen expressing tissue, suggest that the antigen may be or have been present at some level.
Low levels of antigen could be caused by immunoediting as infected cells downregulate their
CEA expression in an effort to circumvent the immune response. This phenomenon has
recently been observed clinically as a method of resistance in breast cancer patients
undergoing treatment with the monoclonal antibody trastuzumab4 5.
Ultimately, with just one control and one lenti-CEAfrac G4S mouse, it is not possible to draw
definitive conclusions. However, it can be said that the available data are promising and suggest
that antigen expression is achieved during the tumorigenesis process. This also has the effect
of slowing the tumor growth rate; all three lenti-CEAfrac tumors outlived the lenti-X controls,
several of them by months. Assuming that lenti-CEAfrac mice do express CEA but that the
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expression level is low as evidenced by IHC, then several approaches can be taken to try to
enhance CEA expression to make antigen targeted therapies more practical. At the molecular
level, versions of CEA could be engineered to retain antibody binding but knock out immune
epitopes, potentially allowing the CEA to better escape immune surveillance. Ultimately,
however, a far superior method would be to engineer a mouse model which expresses CEA
endogenously. Such a model would mimic the human condition, and would be tolerized to CEA
expression. Mice which express CEA endogenously do exist, and making a KP version of these
mice would be a matter of several rounds of breeding between KP and encogenous CEA mice46
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Figure 6.9. Longitudinal pCT imaging of the lungs of KP mice to track tumor burden and growth rate.
Note the difference in the time at which tumors are detected and the rate at which tumors grow and
develop between lenti-X and lenti-CEAfrac G4S mice.
Lung models of cancer present a difficulty in determining tumor burden. The KP mouse model
is especially problematic because the rate of tumorigenesis can be variable. In this work, pCT
was used as a non-invasive method to semi-quantitatively monitor tumor development and
tumor burden in the mice (Figure 6.9). While limited in its resolution to lesions greater than
~1mm in size, pCT is a relatively rapid, inexpensive, and reproducible method of monitoring
these mice. There is the potential of considerably increasing the resolution and contrast of pCT
imaging by using techniques such as respiratory gating or the use of contrast agents.
Respiratory gating synchronizes image acquisition with the breathing of the mouse so that
images are acquired at a consistent point in the breathing of the mouse. This reduces the noise
associated with the movement of internal organs as the mouse breaths, but increase the time
required to image the mice several fold. Alternatively, blood pool contrast agents can
dramatically enhance contrast and help to delineate the organs, particularly the heart, which
are often in the same field of view as the lung and tumor tissue. Contrast agents do place an
additional stress on the animals, and so repeated or frequent use of these agents may not be
47feasible
Another option for monitoring tumor burden would be to use a serum marker. These have
proven useful in clinical situations, and in many cases serum concentrations of markers are
leading indicators of tumor progression 3,48. Unfortunately, no such marker is known in the KP
mouse model. Potential markers include molecules known to be upregulated in many tumors,
such as cytokines and growth factors. A search for such a marker might yield a candidate which
could serve as a surrogate marker for tumor burden and might allow the detection and
quantitation even for small lesions which are under the detection limit of pCT technologies.
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Appendix A: Tumor penetration model and parameters
Numerical simulations of antibody microdistribution are based upon a Krogh cylinder
geometry'. The Krogh cylinder assumes that tissue can be modeled as a cylinder of radius Rkrogh
surrounding a perfused blood vessel which supplies the volume in the cylinder with oxygen and
nutrients. The model is therefore radially symmetric. For the purposes of antibody transport,
numerous analyses and experimental studies have suggested the diffusive transport is the
dominant mode of macromolecular transport within the tumor2 -. Therefore, only diffusive
transport is considered in this model.
This model is implemented in Matlab using the method of lines to discretize over distance and
solve the resulting system of ODEs using the built-in numerical integrators of Matlab. Further
details of a similar implementation can be found at 7. The species considered in this model are
defined below, followed by the governing equations solved in Matlab. Representative
parameter values are also shown; these parameters are valid for the sm3e anti-CEA antibody
and for antigen properties measured or found in the literature for LS174T xenograft tumors.
These parameters can be adjusted for other tumors, antibodies, or macromolecules. Useful
correlations for size effects of molecules on parameters such as void fraction, diffusivity, and
permeability can be found at 8.
Parameter Definition
[Ab] Concentration of free (unbound) antibody in the tumor
[Ag] Concentration of free (unbound) cell surface antigen in the tumor
[M] Concentration of monovalently bound antibody-antigen complexes
[B] Concentration of bivalently bound antibody-antigen complexes
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Krogh cylinder model equations
a[Ab] =D 2[Ab| I ab] 
_2kn [Ab][Ag| +kOff [M]
ata2 r Er
a[Ag] R, 2kon [Ab][Ag]+2kg [B] +k, [M] - k, [Ag]- ko [M][Ag ('", [Ago-2[B]-[M]
=[M] 2kon[Ab][Ag] 
- koff [M] - k, [M]- ko [M][Ageff [Ag]2[B-[M +2k [B]
a[B= ko [M][Ageff 1A'j -2[B|-[M ke [B]-2koff [B]
Initial conditions:
[Ab]= [M] =[B]=0
[Ag] =[Ag]lo = 150 nM (for CEA in LS174T xenografts)
Boundary conditions:
a[Ab] 0
r=RKrogh
P((8c[Ab]piasna)~[Ab]caP =D a [Ab]
(ar r=O)
Where [Ab]pasma is given by:
[Ab 1pism = [Ab plasa ( ae-k"t +,8e- kbt
For all plots, outputs are at t=24 hours post-injection, corresponding to the time of euthanasia
in the experimental data.
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Krogh cylinder model parameter values
Parameter Definition Value Citation
E Tumor void volume 0.2391 8
Mouse blood Volume of blood in ~20 g 2 ml Assumed
volume mouse
D Diffusivity 2.54 x 10 7 cm2/s (8)
P Vascular permeability 3.87 x 10- cm/s (8)
RKrogh Krogh cylinder radius 60 pm Measured
Rcap Capillary radius 8 Im (9)
Kd Monovalent affinity 10 pM Measured
[Ag]eff Effective antigen 550 nM Calculated
concentration for free arm (10)
of monovalently bound
antibody
[Ag]tot Total antigen 150 nM 11,12
concentration (free or
bound)
Rs Steady state antigen ke *[Ag]tot
synthesis rate
kon On rate 2 x 105 M sa Assumed
koff Off rate Kd * kon
ke Antigen endocytosis rate 1.3e-5 s1 13
a Fractional alpha clearance 0.204 Measured
for biexponential plasma
clearance
1 Fractional beta clearance 0.796 Measured
for biexponential plasma
clearance
ka Time constant for a 4.32 h-1  Measured
clearance
kb Time constant for @ 0.024 h- Measured
clearance
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Appendix B: DNA sequence of lentiviral vectors and protein
constructs
Full length CEA (from NCBI)
atggagtctccctcggcccctccccacagatggtgcatcccctggcagaggtcctgctcacagcctcacttctaaccttctggaacccgcc
caccactgccaagctcactattgaatccacgccgttcaatgtcgcagaggggaaggaggtgcttctacttgtccacaatctgccccagcat
ctttttggctacagctggtacaaaggtgaaagagtggatggcaaccgtcaaattataggatatgtaataggaactcaacaagctacccca
gggcccgcatacagtggtcgagagataatataccccaatgcatccctgctgatccagaacatcatccagaatgacacaggattctacacc
ctacacgtcataaagtcagatcttgtgaatgaagaagcaactggccagttccgggtatacccggagctgcccaagccctccatctccagc
aacaactccaaacccgtggaggacaaggatgctgtggccttcacctgtgaacctgagactcaggacgcaacctacctgtggtgggtaaa
caatcagagcctcccggtcagtcccaggtgcagctgtccaatggcaacaggaccctcactctattcaatgtcacaagaaatgacacagc
aagctacaaatgtgaaacccagaacccagtgagtgccaggcgcagtgattcagtcatcctgaatgtcctctatggcccggatgcccccac
catttcccctctaaacacatcttacagatcaggggaaaatctgaacctctcctgccatgcagcctctaacccacctgcacagtactcttggt
ttgtcaatgggactttccagcaatccacccaagagctctttatccccaacatcactgtgaataatagtggatcctatacgtgccaagcccat
aactcagacactggcctcaataggaccacagtcacgacgatcacagtctatgcagagccacccaaacccttcatcaccagcaacaactc
caaccccgtggaggatgaggatgctgtagccttaacctgtgaacctgagattcagaacacaacctacctgtggtgggtaaataatcaga
gcctcccggtcagtcccaggctgcagctgtccaatgacaacaggaccctcactctactcagtgtcacaaggaatgatgtaggaccctatg
agtgtggaatccagaacgaattaagtgttgaccacagcgacccagtcatcctgaatgtcctctatggcccagacgaccccaccatttccc
cctcatacacctattaccgtccaggggtgaacctcagcctctcctgccatgcagcctctaacccacctgcacagtattcttggctgattgat
gggaacatccagcaacacacacaagagctctttatctccaacatcactgagaagaacagcggactctatacctgccaggccaataactc
agccagtggccacagcaggactacagtcaagacaatcacagtctctgcggagctgcccaagccctccatctccagcaacaactccaaac
ccgtggaggacaaggatgctgtggccttcacctgtgaacctgaggctcagaacacaacctacctgtggtgggtaaatggtcagagcctcc
cagtcagtcccaggctgcagctgtccaatggcaacaggaccctcactctattcaatgtcacaagaaatgacgcaagagcctatgtatgtg
gaatccagaactcagtgagtgcaaaccgcagtgacccagtcaccctggatgtcctctatgggccggacacccccatcatttcccccccag
actcgtcttacctttcgggagcgaacctcaacctctcctgccactcggcctctaacccatccccgcagtattcttggcgtatcaatgggata
ccgcagcaacacacacaagttctctttatgccaaaatcacgccaaataataacgggacctatgcctgttttgtctctaacttggctactgg
ccgcaataattccatagtcaagagcatcacagtctctgcatctggaacttctcctggttctcagctgggccactgtcggcatcatgattg
gagtgctggttggggttgctctgatatag
Fractional CEA (CEAfrac)
CEA signal peptide + domains 1 and 2:
(AA 1-34)
(AA 35-144)
(AA 146-237)
(c terminal) (AA 678-702)
Data from NCBI Blast
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Translation:
Fractional CEA w/(G4S)2
Fractional CEA in transfer vector (NLSCre, from Jacks lab)
Sequencing of plasmid backbone from Monte Winslow of Jacks lab. Highlighted and colored
portion represents fractional CEA.
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ggtctctctggttagaccagatctgagcctgggagctctctggcta actagggaaccca ctgctta agcctca ata aagcttgccttgagt
gcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtg
gcgcccgaacagggacttgaaagcgaaagggaaaccagaggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaag
aggcgaggggcggcgactggtgagtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtatt
aagcgggggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaatataaattaaaacatatagtatgg
gcaagcagggagctagaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgtagacaaatactgggacagctacaac
catcccttcaga caggatcaga aga acttagatcattatata atacagtagcaa ccctctattgtgtgcatca aaggatagagataa aag
acaccaaggaagctttagacaagatagaggaagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatcttcagacct
ggaggaggagatatgagggacaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccacca
aggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagca
ctatgggcgcagcgtcaatgacgctgacggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctgagggcta
ttgaggcgcaacagcatctgttgcaactcacagtctggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaag
gatca acagctcctggggatttggggttgctctgga aa actcatttgca ccactgctgtgccttgga atgctagttggagta ata aatctct
ggaacagatttggatcacacgacctggatggagtgggacagagaaattaacaattacacaagcttaatacactccttaattgaagaat
cgcaaaaccagcaagaaaagaatgaacaagaattattggaattagataaatgggcaagtttgtggaattggtttaacataacaaattgg
ctgtggtatataaaattattcataatgatagtaggaggcttggtaggtttaagaatagtttttgctgtactttctatagtgaatagagttagg
cagggatattcaccattatcgtttcagacccacctccca accccgaggggaca attctcgacctcgaga ca aatggcagtattcatccac
aattttaaaagaaaaggggggattggggggtacagtgcaggggaaagaatagtagacataatagcaacagacatacaaactaaagaa
ttacaaaaacaaattacaaaaattcaaaattttcgggtttattacagggacagcagagatccactttggccgcgaatcgatCCTGCAG
GCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAAT
AATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGIATTTACG
GTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGAC
GGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACUTGGCAGTACATCT
ACGTATTAGTCATCGCTATTAaCATGgTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCC
CCTCCCCACCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGCAGCGATGGGGGCGGGGGGGGG
GGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGT
GCGGCGGCAG CCAATCAGAGCGGCGCG CTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCG
GCCCTATAAAAAGCGAAGCGCGCGGCGGGCGGGGAGTCGCTGCGACGCTG CCTTCGCCCCGTGCCCCG
CTCCGCCGCCG CCTCGCG CCGCCCGCCCCGG CTCTGACTGACCGCGTTACTCCCACAGgtgagcgggcgggac
ggcccttctcctccgggctgtaattagcgcttggtttaatgacggcttgtttcttttctgtggctgcgtgaaagccttgaggggctccgggag
ggccctttgtgcggggggagcggctcggggggtgcgtgcgtgtgtgtgtgcgtggggagcgccgcgtgcggctccgcgctgcccggcgg
ctgtgagcgctgcgggcgcggcgcggggctttgtgcgctccgcagtgtgcgcgaggggagcgcggccgggggcggtgccccgcggtgc
ggggggggctgcgaggggaacaaaggctgcgtgcggggtgtgtgcgtgggggggtgagcagggggtgtgggcgcgtcggtcgggctg
caaccccccctgcacccccctccccgagttgctgagcacggcccggcttcgggtgcggggctccgtacggggcgtggcgcggggctcgcc
gtgccgggcggggggtggcggcaggtgggggtgccgggcggggcggggccgcctcgggccggggagggctcgggggaggggcgcgg
cggcccccggagcgccggcggctgtcgaggcgcggcgagccgcagccattgccttttatggtaatcgtgcgagagggcgcagggacttc
ctttgtcccaaatctgtgcggagccgaaatctgggaggcgccgccgcaccccctctagcgggcgcggggcgaagcggtgcggcgccggc
aggaaggaaatgggcggggagggcttcgtgcgtcgccgcgccgccgtccccttctccctctccagcctcggggctgtccgcgggggga
cggctgccttcgggggggacggggcagggcggggttcggcttctggcgtgtgaccggcggctctagacaattgtactaaccttcttctcttt
cctctcctgacagGTTGGTGTACAGTAGCTTggcgcgccaccATGCCCAAGAAGAAGAGGAAGGTGTCCAATTT
ACTGACCGTACACCAAAATTTGCCTGCATTACCGGTCGATGCAACGAGTGATGAGGTTCGCAAGAACCT
GATGGACATGTTCAGGGATCGCCAGGCGTTTTCTGAGCATACCTGGAAAATGCTTCTGTCCGTTTGCCG
GTCGTGGGCGGCATGGTGCAAGTTGAATAACCGGAAATGGTTTCCCGCAGAACCTGAAGATGTTCGCG
ATTATCTTCTATATCTTCAGGCGCGCGGTCTGGCAGTAAAAACTATCCAGCAACATTTGGGCCAGCTAAA
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CATGCTTCATCGTCGGTCCGGGCTGCCACGACCAAGTGACAGCAATGCTGTTTCACTGGTTATGCGGCG
GATCCGAAAAGAAAACGTTGATGCCGGTGAACGTGCAAAACAGGCTCTAGCGUTCGAACGCACIGA1TT
CGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCAUTTCTGGG
GATTGCTTATAACACCCTGTTACGTATAGCCGAAATTGCCAGGATCAGGGTTAAAGATATCTCACGTACT
GACGGTGGGAGAATGTTAATCCATATTGGCAGAACGAAAACGCTGGTTAGCACCGCAGGTGTAGAGAA
GGCACTTAGCCTGGGGGTAACTAAACTGGTCGAGCGATGGATCCGTCTCTGGTGTAGCTGATGATCC
GAATAACTACCTGTTTTGCCGGGTCAGAAAAAATGGTGTTGCCGCGCCATCTGCCACCAGCCAGCTATCA
ACTCGCGCCCTGGAAGGGATTGAAGCAACTCATCGATTGATUTACGGCGCTAAGGATGACTCTGGT
CAGAGATACCTGG CCTG GTCTGGACACAGTG CCCGTGTCG GAG CCG CG CGAGATATGG CCCG CG CTG G
AGTTTCAATACCGGAGATCATGCAAGCTGGTGGCTGGACCAATGTAAATA1TGTCATGAACTATATCCGT
AACCTGGATAGTGAAACAGGGGCAATGGTGCGCCTGCTGGAAGATGGCGATgggccggccggctccggcgag
ggcagggagtttctacagcgggactggggaaatccggccaaat
aattaagctagcgatatcgtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgCttcc
cgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtg
cactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctccctattgcc
acggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaag
ctgacgtcctttccatggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcg
gaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcc
tccccgcctgtttcgcctcggcgtccggtctagaggtacctttaagaccaatgacttacaaggcagctgtagatcttagccactttttaaaa
gaaaaggggggactggaagggctaattcactcccaacgaagacaagatctgctttttgcttgtactgggtctctctggttagaccagatct
gagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtct
gttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctCtagcagtagtagttcatgtcatcttattattca
gtatttataacttgcaaagaaatgaatatcagagagtgagaggaacttgtttattgcagcttataatggttacaaataaagcaatagcatc
acaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggctctagctatc
ccgccccta actccgcccatcccgccccta actccgcccagttccgcccattctccgccccatggctga cta attttttttatttatgca gag
gccgaggccgcctcggcctctgagctattccagaagtagtgaggaggcttttttggaggcctagggacgtacccaattcgccctatagtga
gtcgtattacgcgcgctcactggccgtcgttttacaacgtcgtgactgggaaaaccctggcgttacccaacttaatcgccttgcagcacatc
cccctttcgccagctggcgtaatagcgaagaggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatgggacgcg
ccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcg
ctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacgg
cacctcgaccccaaaaaacttgattagggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtc
cacgttctttaatagtggactcttgttccaaactggaacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatt
tcggcctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgcttacaatttaggtggcactttt
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cggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgct
tcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgctc
acccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaa
gatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacgc
cgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatgg
catgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccga
aggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagtgaatgaagccataccaaacg
acgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaac
aattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctgg
agccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacggggag
tcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactc
atatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatcccttaa
cgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatctgtgcttg
caaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggttcagcaga
gcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgct
aatcctgttaccagtggctgctgccagtggcgataagtcgtgtttaccgggttggactcaagacgatagttaccggataaggcgcagcg
gtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatga
gaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagct
tccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggc
ggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcccc
tgattctgtggataaccgtattaccgcctttgagtgagtgataccgctcgccgcagccgaacgaccgagcgcagcgagtcagtgagcga
ggaagcggaagagcgcccaatacgcaaaccgcctctccccgcgcgttggccgattcattaatgcagctggcacgacaggtttcccgact
ggaaagcgggcagtgagcgcaacgcaattaatgtgagttagctcactcattaggcaccccaggtttacactttatgcttccggtcgtat
gttgtgtggaattgtgagcggataacaatttcacacaggaaacagctatgaccatgattacgccaagcgcgcaattaaccctcactaaag
ggaacaaaagctggagctgcaagcttaatgtagtcttatgcaatactcttgtagtttgcaacatggtaacgatgagttagcaacatgcct
tacaaggagagaaaaagcaccgtgcatgccgattggtggaagtaaggtggtacgatcgtgccttattaggaaggcaacagacgggtct
gacatggattggacgaaccactgaattgccgcattgcagagatattgtatttaagtgcctagctcgatacataaacg
Full length CEA in transfer vector
Sequencing from Monte Winslow of Jacks lab. Highlighted and colored portion represents CEA,
which has been ~80% sequenced and appears to be okay. Total length of plasmid 10934 bp, of
which 2109 is CEA.
ggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagt
gcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtg
gcgcccgaacagggacttgaaagcgaaagggaaaccagaggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaag
aggcgaggggcggcgactggtgagtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtatt
aagcgggggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaatataaattaaaacatatagtatgg
gcaagcagggagctagaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgtagacaaatactgggacagctacaac
catcccttcagacaggatcagaagaacttagatcattatataatacagtagcaaccctctattgtgtgcatcaaaggatagagataaaag
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acaccaaggaagctttagacaagatagagga agagcaa aacaaaagtaagaccaccgcacagcaagcggccgctgatcttcagaCCt
ggaggaggagatatgagggacaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccacca
aggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagca
ctatgggcgcagcgtcaatgacgctgacggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctgagggcta
ttgaggcgcaacagcatctgttgcaactcacagtctggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaag
gatca acagctcctggggatttggggttgctctggaa aactcatttgcacca ctgctgtgccttgga atgctagttggagta ata aatctct
gga acagatttgga atcaca cgacctggatggagtggga cagaga aatta acaattacaca agctta atacactcctta attga aga at
cgca a aaccagca aga a aaga atga aca aga attattgga attagata aatgggca agtttgtgga attggtttaacataa caaattgg
ctgtggtatata aaattattcataatgatagtagga ggcttggtaggttta aga atagtttttgctgtactttctatagtga atagagttagg
cagggatattcaccattatcgtttcagacccacctcccaaccccgaggggacaattctcgacctcgagacaaatggcagtattcatccac
aattttaaaagaaaaggggggattggggggtacagtgcaggggaaagaatagtagacataatagcaacagacatacaaactaaagaa
ttacaaaaacaaattacaaaaattcaaaattttcgggtttattacagggacagcagagatccactttggccgcgaatcgatCCTGCAG
GCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAAT
AATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCAUTGACGTCAATGGGTGGAGTAWTACG
GTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGAC
GGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCT
ACGTATTAGTCATCGCTATTAaCATGgTCGAGGTGAGCCCCACGTTCTGCTTCACTCTCCCCATCTCCCCCC
CCTCCCCACCCCCAATTTTGTATTTATTTA11TTTTAATTATTTTGTGCAGCGATGGGGGCGGGGGGGGG
GGGGGGGCGCGCGCCAGGCGGGGCGGGGCGGGGCGAGGGGCGGGGCGGGGCGAGGCGGAGAGGT
GCGGCGGCAG CCAATCAGAGCGGCGCGCTCCGAAAGTTTCCTTATGGCGAGGCGGCGGCGGCGGCG
GCCCTATAAAAAGCGAAGCGCGCGGCGGGCGGGGAGTCGCTGCGACGCTGCCTTCGCCCCGTGCCCCG
CTCCGCCGCCG CCTCGCGCCGCCCGCCCCGG CTCTGACTGACCGCGTTACTCCCACAGgtgagcgggcgggac
ggcccttctcctccgggctgta attagcgcttggttta atgacggcttgtttcttttctgtggctgcgtga aagccttgaggggctccgggag
ggccctttgtgcggggggagcggctcggggggtgcgtgcgtgtgtgtgtgcgtggggagcgccgcgtgcggctccgcgctgcccggcgg
ctgtgagcgctgcgggcgcggcgcggggctttgtgcgctccgcagtgtgcgcgaggggagcgcggccgggggcggtgccccgcggtgc
ggggggggctgcgaggggaacaaaggctgcgtgcggggtgtgtgcgtgggggggtgagcagggggtgtgggcgcgtcggtcgggctg
caaccccccctgcacccccctccccgagttgctgagcacggcccggcttcgggtgcggggctccgtacggggcgtggcgcggggctcgcc
gtgccgggcggggggtggcggcaggtgggggtgccgggcggggcggggccgcctcgggccggggagggctcgggggaggggcgcgg
cggcccccggagcgccggcggctgtcgaggcgcggcgagccgcagccattgccttttatggtaatcgtgcgagagggcgcagggacttc
ctttgtcccaaatctgtgcggagccgaaatctgggaggcgccgccgcaccccctctagcgggcgcggggcgaagcggtgcggcgccggc
aggaaggaaatgggcggggagggccttcgtgcgtcgccgcgccgccgtccccttctccctctccagcctcggggctgtccgcgggggga
cggctgccttcgggggggacggggcagggcggggttcggcttctggcgtgtgaccggcggctctagacaattgtactaaccttcttctCttt
cctctcctgacagGTTGGTGTACAGTAGCTTggcgcgccaccATGCCCAAGAAGAAGAGGAAGGTGTCCAATTT
ACTGACCGTACACCAAAATTTGCCTGCATTACCGGTCGATGCAACGAGTGATGAGGTTCGCAAGAACCT
GATGGACATGTTCAGGGATCGCCAGGCGTFFTCTGAGCATACCTGGAAAATGCTTCTGTCCGTUTGCCG
GTCGTGGGCGGCATGGTGCAAGUTGAATAACCGGAAATGG1TTCCCGCAGAACCTGAAGATGTFCGCG
ATTATCTTCTATATCTTCAGGCGCGCGGTCTGGCAGTAAAAACTATCCAGCAACATTTGGGCCAGCTAAA
CATGCTTCATCGTCGGTCCGGGCTGCCACGACCAAGTGACAGCAATGCTGTTTCACTGGTTATGCGGCG
GATCCGAAAAGAAAACGUTGATGCCGGTGAACGTGCAAAACAGGCTCTAGCGTTCGAACGCACTGATUT
CGACCAGGTTCGTTCACTCATGGAAAATAGCGATCGCTGCCAGGATATACGTAATCTGGCATTTCTGGG
GATTGCTTATAACACCCTGTTACGTATAGCCGAAATTGCCAGGATCAGGGTTAAAGATATCTCACGTACT
GACGGTGGGAGAATGTTAATCCATATTGGCAGAACGAAAACGCTGGUTAGCACCGCAGGTGTAGAGAA
GGCACTTAGCCTGGGGGTAACTAAACTGGTCGAGCGATGGATTTCCGTCTCTGGTGTAGCTGATGATCC
GAATAACTACCTGTTTTGCCGGGTCAGAAAAAATGGTGTTGCCGCGCCATCTGCCACCAGCCAGCTATCA
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ACTCGCGCCCTGGAAGGGA1TTTTGAAGCAACTCATCGATTGATTTACGGCGCTAAGGATGACTCTGGT
CAGAGATACCTG GCCTG GTCTGGACACAGTG CCCGTGTCG GAG CCG CG CGAGATATGGCCCG CGCTGG
AGTTTCAATACCGGAGATCATGCAAGCTGGTGGCTGGACCAATGTAAATATTGTCATGAACTATATCCGT
AACCTGGATAGTGAAACAGGGGCAATGGTGCGCCTGCTGGAAGATGGCGATgggccggccggctccggcgag
ggcaggggaagtcttctaacatgcggggacgtggaggaaaatcccggcccagaattcatggagtctccctcggcccctccccacagatg
gtgcatcccctggcagaggctcctgctcacagcctcacttctaaccttctggaacccgcccaccactgccaagctcactattgaatccacg
ccgttca atgtcgcagagggga aggaggtgcttcta cttgtcca ca atctgccccagcatctttttggcta cagctggtacaa aggtgaaa
gagtggatggcaaccgtcaaattataggatatgtaataggaactcaacaagctaccccagggcccgcatacagtggtcgagagataata
ta cccca atgcatccctgctgatccagaacatcatccaga atgacacaggattctaca cccta ca cgtcata aagtcagatcttgtga atg
aagaagcaactggccagttccgggtatacccggagctgcccaagccctccatctccagcaacaactccaaacccgtggaggacaagga
tgctgtggccttcacctgtga acctgagactcaggacgcaaccta cctgtggtgggta a aca atcagagcctcccggtcagtcccaggct
gcagctgtcca atggca acagga ccctcactctattca atgtca ca aga aatgacacagca agctaca aatgtgaaacccaga accca
gtgagtgccaggcgcagtgattcagtcatcctgaatgtcctctatggcccggatgcccccaccatttcccctctaaacacatcttacagatc
a gggga a aatctga acctctcctgccacgca gcctcta accca cctgca cagtactcttggtttgtca atgggactttccagca atccacc
ca aga gctcttt atcccca acatcactgtga at aata gtggat cctata cgtgcca agcccata actcagacactggcctcaataggacc
acagtcacgacgatcacagtctatgcagagccacccaaacccttcatcaccagcaacaactccaaccccgtggaggatgaggatgctgt
agccttaacctgtgaacctgagattcagaacacaacctacctgtggtgggtaaataatcagagcctcccggtcagtcccaggctgcagct
gtcca atga ca acagga ccctca ctcta ctcagtgtcaca aggaatgatgtaggaccctatgagtgtgga atccaga acgaattaagtgt
tgaccacagcgacccagtcatcctgaatgtcctctatggcccagacgaccccaccatttccccctcatacacctattaccgtccaggggtg
a acctca gcctctcctgccatgcagcctcta accca cctgca ca gtattcttggctgattgatgggaacatccagcaaca cacacaaga g
ctctttatctcca acatcactgaga aga acagcgga ctctata cctgccaggcca ata actcagccagtggccacagcaggactacagtc
aagacaatcacagtctctgcggagctgcccaagccctccatctccagcaacaactccaaacccgtggaggacaaggatgctgtggcctt
cacctgtga acctgaggctcagaaca ca accta cctgtggtgggta aatggtcagagcctcccagtcagtcccaggctgcagctgtcca a
tggcaacaggaccctcactctattcaatgtcacaagaaatgacgcaagagcctatgtatgtggaatccagaactcagtgagtgcaaacc
gcagtgacccagtcaccctggatgtcctctatgggccggacacccccatcatttcccccccagactcgtcttacctttcgggagcgaacctc
a acctctcctgccactcggcctcta acccatccccgcagtattcttggcgtatca atgggataccgcagca acacacaca agttctctttat
cgcca a aatca cgcca aata ata acgggacctatgcctgttttgtctcta acttggctactggccgcaataattccatagtcaagagcatc
acagtctctgcatctggaacttctcctggtctctcagctggggccactgtcggcatcatgattggagtgctggttggggttgctctgatatag
ttaattaagctagcgatatcgtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgcttc
ccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgt
gcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctccctattgc
cacggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaa
gctgacgtcctttccatggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagc
ggaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgc
ctccccgcctgtttcgcctcggcgtccggtctagaggtacctttaagaccaatgacttacaaggcagctgtagatcttagccactttttaaa
agaaaaggggggactggaagggctaattcactcccaacgaagacaagatctgctttttgcttgtactgggtctctctggttagaccagat
ctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgt
ctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtgga a aatctctagcagtagtagttcatgtcatcttattattc
agtatttataacttgcaaagaaatgaatatcagagagtgagaggaacttgtttattgcagcttataatggttacaaataaagcaatagca
tcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggctctagcta
tcccgcccctaactccgcccatcccgcccctaactccgcccagttccgcccattctccgccccatggctgactaattttttttatttatgcaga
ggccgaggccgcctcggcctctgagctattccagaagtagtgaggaggcttttttggaggcctagggacgtacccaattcgccctatagtg
agtcgtattacgcgcgctcactggccgtcgtttta ca acgtcgtgactggga aaaccctggcgttaccca actta atcgccttgcagcaca
tccccctttcgccagctggcgtaatagcgaagaggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatgggacgc
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gccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttc
gctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacg
gcacctcgaccccaaaaaacttgattagggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagt
ccacgttctttaatagtggactcttgttccaaactggaacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgat
ttcggcctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgcttacaatttaggtggcacttt
tcggggaaatgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgc
ttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcattttgccttcctgtttttgct
cacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggta
agatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattgacg
ccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatg
gcatgacagtaagagaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcggaggaccg
aaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagccataccaaac
gacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaa
caattaatagactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctg
gagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagttatctacacgacgggga
gtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttact
catatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatccctta
acgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatctgctgctt
gcaaacaaaaaaaccaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcag
agcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacatacctcgctctgc
taatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagc
ggtcgggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatg
agaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagcgcacgagggagc
ttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggc
ggagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctcacatgttctttcctgcgttatcccc
tgattctgtggataaccgtattaccgcctttgagtgagtgataccgctcgccgcagccgaacgaccgagcgcagcgagtcagtgagcga
ggaagcggaagagcgcccaatacgcaaaccgcctctccccgcgcgttggccgattcattaatgcagctggcacgacaggtttcccgact
ggaaagcgggcagtgagcgcaacgcaattaatgtgagttagctcactcattaggcaccccaggctttacactttatgcttccggctcgtat
gttgtgtggaattgtgagcggataacaatttcacacaggaaacagctatgaccatgattacgccaagcgcgcaattaaccctcactaaag
ggaacaaaagctggagctgcaagcttaatgtagtcttatgcaatactcttgtagtcttgcaacatggtaacgatgagttagcaacatgcct
tacaaggagagaaaaagcaccgtgcatgccgattggtggaagtaaggtggtacgatcgtgccttattaggaaggcaacagacgggtct
gacatggattggacgaaccactgaattgccgcattgcagagatattgtatttaagtgcctagctcgatacataaacg
Murine sm3e LC in gWiz plasmid
Gwiz backbone shown in this sequence as unaltered text
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TCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCCGGAGACGGTCACAGCTTGTC
TGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGG
CTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATATGCGGTGTGAAATACCGCA
CAGATGCGTAAGGAGAAAATACCGCATCAGATTGGCTATTGGCCATTGCATACGTTGTATCCATATCATA
ATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGTTGACATTGATTATTGACTAGTTATTAAT
AGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAA
TGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTA
ACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTA
CATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATT
ATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACC
ATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGT
CTCCACCCCATTGACGTCAATGGGAGTTTG1-MGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTA
ACAACTCCGCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCT
CGTTTAGTGAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGG
GACCGATCCAGCCTCCGCGGCCGGGAACGGTGCATTGGAACGCGGATTCCCCGTGCCAAGAGTGACGT
AAGTACCGCCTATAGACTCTATAGGCACACCCCTTTGGCTCTTATGCATGCTATACTGTTTTTGGMGGG
GCCTATACACCCCCGCTTCCTTATGCTATAGGTGATGGTATAGCTTAGCCTATAGGTGTGGGTTATTGAC
CATTATTGACCACTCCCCTATTGGTGACGATACTTTCCATTACTAATCCATAACATGGCTCTTTGCCACAAC
TATCTCTATTGGCTATATGCCAATACTCTGTCCTTCAGAGACTGACACGGACTCTGTATTTTTACAGGATG
GGGTCCCATTTATTATTTACAAATTCACATATACAACAACGCCGTCCCCCGTGCCCGCAGTTTTTATTAAA
CATAGCGTGGGATCTCCACGCGAATCTCGGGTACGTGTTCCGGACATGGGCTCTTCTCCGGTAGCGGCG
GAG CTTCCACATCCGAGCCCTGGTCCCATGCCTCCAGCGG CTCATGGTCGCTCGGCAGCTCCTTGCTCCT
AACAGTGGAGGCCAGACTTAGGCACAGCACAATGCCCACCACCACCAGTGTGCCGCACAAGGCCGTGG
CGGTAGGGTATGTGTCTGAAAATGAGCGTGGAGATTGGGCTCGCACGGCTGACGCAGATGGAAGAM
AAGGCAGCGGCAGAAGAAGATGCAGGCAGCTGAGTTGTTGTATTCTGATAAGAGTCAGAGGTAACTCC
CGTTGCGGTGCTGTTAACGGTGGAGGGCAGTGTAGTCTGAGCAGTACTCGTTGCTGCCGCGCGCGCCA
CCAGACATAATAGCTGACAGACTAACAGACTGTTCCTTTCCATGGGTC
m CGTGTGATCAGATATCGCGGCCGCTCTAG
ACCAGGCGCCTGGATCCAGATCACTTCTGGCTAATAAAAGATCAGAGCTCTAGAGATCTGTGTGTTGGT
TTTTTGTGGATCTGCTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGAC
CCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGG
TGTCATTCTATTCTGGGGGGTGGGGTGGGGCAGCACAGCAAGGGGGAGGATTGGGAAGACAATAGCA
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GGCATGCTGGGGATGCGGTGGGCTCTATGGGTACCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT
CTCGGTACCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCGGTACCAGGTGCTGAAGAATTGA
CCCGGTTCCTCCTGGGCCAGAAAGAAGCAGGCACATCCCCTTCTCTGTGACACACCCTGTCCACGCCCCT
GGTTCTTAGTTCCAGCCCCACTCATAGGACACTCATAGCTCAGGAGGGCTCCG CCTTCAATCCCACCCGC
TAAAGTACTTGGAGCGGTCTCTCCCTCCCTCATCAG CCCACCAAACCAAACCTAGCCTCCAAGAGTGGGA
AGAAATTAAAGCAAGATAGGCTATTAAGTGCAGAGGGAGAGAAAATGCCTCCAACATGTGAGGAAGTA
ATGAGAGAAATCATAGAATTTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCG
GCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAA
AGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGT1TTTC
CATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACA
GGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGC
TTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCAATGCTCACGCTGTAGGTAT
CTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCT
GCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGC
CACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTDGAAGTGGTGGCCTA
ACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAA
GAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGG11111T1GTTTGCAAGCAGC
AGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTGACGCTCAGT
GGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTT
AAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGC
TTAATCAGTGAGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCGGGGGG
GGGGGGCGCTGAGGTCTGCCTCGTGAAGAAGGTGTTGCTGACTCATACCAGGCCTGAATCGCCCCATCA
TCCAGCCAGAAAGTGAGGGAGCCACGGTTGATGAGAGCTTTGTTGTAGGTGGACCAGTTGGTGATTTT
GAACTTTTGCTTTGCCACGGAACGGTCTGCGTTGTCGGGAAGATGCGTGATCTGATCCTTCAACTCAGCA
AAAGTTCGATTTATTCAACAAAGCCGCCGTCCCGTCAAGTCAGCGTAATGCTCTGCCAGTGTTACAACCA
ATTAACCAATTCTGATTAGAAAAACTCATCGAGCATCAAATGAAACTGCAATTTATTCATATCAGGATTAT
CAATACCATATTTGAAAAAGCCGTTTCTGTAATGAAGGAGAAAACTCACCGAGGCAGTCCATAGGA
TGGCAAGATCCTGGTATCGGTCTGCGATTCCGACTCGTCCAACATCAATACAACCTATTAATTTCCCCTCG
TCAAAAATAAGGTTATCAAGTGAGAAATCACCATGAGTGACGACTGAATCCGGTGAGAATGGCAAAAG
CTTATGCATTTCTTTCCAGACTTGTTCAACAGGCCAGCCATTACGCTCGTCATCAAAATCACTCGCATCAA
CCAAACCGTTATTCATTCGTGATTGCGCCTGAGCGAGACGAAATACGCGATCGCTGTTAAAAGGACAAT
TACAAACAGGAATCGAATGCAACCGGCGCAGGAACACTGCCAGCGCATCAACAATATTTTCACCTGAAT
CAGGATATTCTTCTAATACCTGGAATGCTGTTTTCCCGGGGATCGCAGTGGTGAGTAACCATGCATCATC
AGGAGTACGGATAAAATGCTTGATGGTCGGAAGAGGCATAAATTCCGTCAGCCAGTTTAGTCTGACCAT
CTCATCTGTAACATCATTGGCAACGCTACCTTTGCCATGTTTCAGAAACAACTCTGGCGCATCGGGCTTCC
CATACAATCGATAGATTGTCGCACCTGATTGCCCGACATTATCGCGAGCCCATTTATACCCATATAAATCA
GCATCCATGTTGGAATTTAATCGCGGCCTCGAGCAAGACGTTTCCCGTTGAATATGGCTCATAACACCCC
TTGTATTACTGTTTATGTAAGCAGACAGTTTATTGTTCATGATGATATATTTTTATCTTGTGCAATGTAAC
ATCAGAGATTTTGAGACACAACGTGGCTTTCCCCCCCCCCCCATTATTGAAGCATTTATCAGGGTTATTGT
CTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCC
GAAAAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGCGTATCAC
GAGGCCCTTTCGTC
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Murine sm3e HC insert
AGATGGGTTGGAGCCTCATCTTGCTCTTCCTTGTCGCTGTTGCTACGACGCG~
AGCCCAGAGTGCCCATAACACAGAACCCCTGTCCTCCACTCAAAGAGTGTCCCCC
ATGCGCAGCTCCAGACCTCTTGGGTGGACCATCCGTCTTCATCTTCCCTCCAAAGATCAAGGATGTACTC
ATGATCTCCCTGAGCCCCATGGTCACATGTGTGGTGGTGGATGTGAGCGAGGATGACCCAGACGTCCAG
ATCAGCTGGTTTGTGAACAACGTGGAGTACACACAGCTCAGACACNAACCCATAGAGAGGATTACACA
GTACTCTCGGTGTCAGTGCCTCCCATCCAGCACAGNCTGNTGAGTGCAGGAGTTCAATGCAAGNCAACN
ACNAGTCCTCCATCCCCATCGAGAAAACNTTCTCAACCCN NAGG N NGTANANCTCCCAN N N NTATGGT
CNTGG
Lenti-GFP transfer vector
This vector was a generous gift from Tyler Jacks' lab, and the sequence has been published
online at http://www.addgene.org/20781/
The lenti-X vector was also obtained from the Jacks lab, although sequencing information for
this vector was not readily available
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